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List of Definitions of Key Terms 
Left Ventricle Ejection Fraction (LVEF): The volume of blood ejected 
from the left ventricle during each systole can be expressed as 
a percentage of the end-diastolic volume. This gives the 
ejection fraction. The normal LVEF value is between 52% and 
75% (Anderson et a/., 1993). 
Echocardiography: This produces cardiac images by reflecting pulses 
of ultrasound from the structures of the heart and then 
recording the reflected sound signals (Anderson et a/., 1993). 
CD4: T-helper cell (Miller, 2000b). 
CD4 Cell Count: A measure of the cumulative damage caused to 
the immune system by infection with HIV. It is measured as 
cells/ml (Allen et al, 2000). The normal value range for the 
CD4 cell count is between 510 - 1310 cells/ml (University of 
the Free State, 1997/8). 
Viral Load: The level of virus in plasma (Allen et al, 2000). By six 
months after infection, viraemia stabilizes at a constant level, 
or "set point". The quantity of viral RNA measured in the blood 
after this set point has been achieved, is known as the "viral 
load" (Miller, 2000b). In patients without HIV/AIDS infection 
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there will be no HIV RNA copies in the blood. Therefore the 
normal value for HIV viral load will be 0 RNA copies/ml. 
HAART: Highly active antiretroviral therapy consists of a multi-
drug combination, usually three but can also be four, using 
drugs that inhibit different steps in the HIV replication cycle to 
achieve the greatest viral suppression. This can be two NRTIs 
plus one PI or NNRTI, or two PIs or various other combinations 
(Makotoko, 2003). 
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Jsummary 
This research project compared the influence of the CD4 cell count, 
the viral load and antiretroviral therapy (ARn on the left ventricle 
ejection fraction (LVEF). The purpose was to see what the 
relationship between the variables was in an attempt to find a point in 
the course of the HIV/AIDS disease where it is necessary to do an 
echocardiogram on these patients to evaluate the LVEF. All the data 
of the variables were included against the inclusion and exclusion 
criteria. An echocardiogram was done on all those HIV/AIDS 
diagnosed patients who gave their consent to evaluate the LVEF. The 
patients then went for their usual blood tests and ART was given if it 
was indicated. The findings show that there was a direct proportional 
relationship between the LVEF and the CD4 cell count, and an indirect 
proportional relationship between the viral load and the LVEF. The 
prevalence of a below normal LVEF was mostly found in patients 
whose CD4 cell count was below or equal to 100 cells/ml and/or the 
viral load above or equal to 100 000 RNA copies/ml. The majority of 
patients whose LVEF was below normal and whose viral load was 
equal to or below 100 000 RNA copies/ml were on antiretroviral 
therapy. When the viral load exceeded the cut-off point of 100 000 
RNA copies/ml, the patients who were not on ART with a below 
J 
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normal LVEF exceeded those who were on ART. The majority of 
patients with a low CD4 cell count whose LVEF was below normal 
were not on antiretroviral therapy. It was also found that the ART had 
a direct positive effect on the CD4 cell count and the viral load, and 
indirectly on the LVEF. Therefore, because of the relationship 
between the CD4 cell count and the LVEF and the viral load and the 
LVEF, ART had an indirect effect on the LVEF via the CD4 cell count 
and/or the viral load. This means that if there was an increase in the 
CD4 cell count due to the ART, then one could expect to see a rise in 
the LVEF because of the direct proportional relationship between the 
CD4 cell count and the LVEF. If the ART led to a decrease in the viral 
load, then one could expect that the LVEF would increase due to an 
indirect proportional relationship between the viral load and the LVEF. 
Successful antiretroviral therapy had a positive effect on the CD4 cell 
count and the viral load, and an indirect positive effect on the LVEF 
(via the CD4 cell count and/or the viral load). 
To conclude, the treating physician of ~n adult HIV/AIDS patient 
should consider an echocardiogram on all these patients when the 
CD4 cell count falls below 100 copies/ml, and/or when the viral load 
exceeds 100 000 RNA copies/ml in order to identify those patients 
who have left ventricular dysfunction and who might therefore benefit 
from treatment with appropriate medication. 
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lopsomming 
Hierdie navorsingsprojek het die invloed van die CD4 seltelling, die 
viruslading en die antiretrovirale behandeling (ARB) op die linker 
ventrikulere uitwerpfraksie (LVUF) bestudeer. Die doel was om te sien 
wat die verwantskap was tussen hierdie veranderlikes in 'n poging om 
'n punt vas te stel in die verloop van die MIV/VIGS siekte waar dit 
belangrik is om 'n eggokardiogram te doen om die LVUF te bepaal. 
Aile data en veranderlikes was ingesluit teen die insluitings- en 
uitsluitingskriterias. 'n Eggokardiogram is gedoen op aile MIV/VIGS 
pasiente wat toestemming gegee het, om die LVUF te evalueer. Die 
pasiente het daarna vir hulle gereelde bloedtoetse gegaan en ARB is, 
indien nodig, vir hulle voorgeskryf. Die bevindinge wys dat daar 'n 
direkte eweredige verwantskap is tussen die CD4 seltelling en die 
LVUF en dat daar 'n indirekte eweredige verwantskap is tussen die 
viruslading en die LVUF. Die voorkoms van die LVUF om onder 
normaal te wees, het die meeste voorgek0m by pasiente wie se CD4 
seltelling onder of gelyk aan 100 selle/ml was en/of wie se viruslading 
bo of gelyk aan 100 000 RNA kopie/ml was. Uit aile pasiente wie se 
LVUF onder normaal was en virusladingtoetse gehad het, was die 
meeste op ARB tot en met die afsnypunt van ::5100 000 RNA 
kopie/ml. Wanneer die viruslading die afsnypunt van 100 000 RNA 
kopie/ml oorskry het, was die pasiente wat op geen ARB was meer as 
I 
© Central University of Technology, Free State
Influence of eD4, Viral load and ART on L VEF Steenkamp xvii 
die wat op ARB was. Uit aile pasiente wat 'n CD4 seltelling en 'n LVUF 
van onder normaal gehad het, was die meeste op geen ARB nie. Daar 
is ook gevind dat die ARB 'n positiewe uitwerking op die CD4 
seltelling en/of die viruslading gehad het, maar nie 'n direkte invloed 
op die LVUF nie. Daarom, as gevolg van die verhouding tussen die 
CD4 seltelling en die LVUF en die viruslading en die LVUF, het die 
ARB 'n indirekte effek op die LVUF via die CD4 seltelling en/of die 
viruslading. Dit beteken dat 'n toename in die CD4 seltelling as gevolg 
van die ARB, heel moontlik 'n toename in die LVUF tot gevolg het, as 
gevolg van hulle direkte eweredige vewantskap. Indien die ARB tot 'n 
afname in die viruslading lei, kan 'n toename in die LVUF verwag 
word, as gevolg van die indirekte eweredige verwantskap tussen 
hulle. Die suksesvolle antiretrovirale behandeling het 'n positiewe 
effek op die CD4 seltelling en op die viruslading en 'n indirekte 
positiewe effek op die LVUF (via die CD4 seltelling en/of die 
viruslading). 
Die slotsom is dus dat aile behandelende g~neeshere van MIV/VIGS 
pasiente 'n eggokardiogram goed moet oorweeg, sodra die virus 
lading bo 100 000 RNA kopie/ml is en/of die CD4 seltelling onder 100 
selle/ml is, sodat die pasiente met linkerventrikulere wanfunksie 
ge'identifiseer kan word en hulle die nodige behandeling daarvoor kan 
ontvang. 
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South Africa had an estimated 5 million people - children and adults -
living with HIV infection and AIDS at the end of 2001 (UNAIDS/WHO, 
2002). The researcher recognised many patients diagnosed with HIV 
infection that presented with left ventricular dysfunction or congestive 
cardiac failure. There have been publications in the medical literature 
linking HIV infection and AIDS with left ventricular dysfunction but 
none from South Africa (Currie et al, 1998; Schlant & Alexander, 
1994; Lipshultz et al, 1998; Barbaro et al., 1998b; Hivdent, 1998; 
Millei et al., 1998; Murphy, 1999; Rerkpattanapipat et al, 2000; 
Pugliese et al, 2000; ACierno, 1989; Warkentin, 1998; Yunis and 
Stone, 1998). In South Africa little is known about the influence of 
HIV/AIDS on the LVEF. 
A review by Millei et al (1998) highlighted the fact that there are very 
few clinical studies on this topic. Current knowledge is based almost 
exclusively on echocardiography and autopsy studies. Observational 
or clinical trials based on syndromes of heart failure, tamponade and 
so forth would be useful. There is also ve,ry little information on the 
impact of antiretroviral therapy on the LVEF. Finally, because cardiac 
complications are often clinically inapparent or subtle in the initial 
stages, periodic screening of HIV-positive patients by ECG and 
echocardiogram is probably indicated. The use of routine 
electrocardiography and echocardiography for asymptomatic patients 
with HIV infection is controversial (Millei et al, 1998). 
CENTRALuNrveRSfTYOF 
TECHNOLOGY, FREE STATE 
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Echocardiographic examination is more informative and sensitive than 
electrocardiographic monitoring. Indeed, echocardiography appears 
to be the most appropriate way to detect heart involvement during 
HIV infection; it allows for early diagnosis and thus provides time to 
find the most suitable way of treating cardiac abnormalities, even in 
the early asymptomatic phase of the disease. Prompt recognition and 
treatment is important because palliative therapy with diuretics and 
vasodilators can be worthwhile: mild global left ventricular 
dysfunction appears to be reversible in many patients and a sub-
group progresses to symptomatic heart failure without treatment. It 
appears prudent to perform a careful cardiac examination at the time 
of diagnosis of HIV to obtain a baseline functional assessment. An 
echocardiogram should be performed if there are signs of heart 
disease (Millei et al., 1998; Warkentin, 1998). HIV/AIDS related 
cardiomyopathy is a diagnostic challenge to which physicians should 
remain alert (Yunis et at, 1998). A need was identified to study 
further the relationship between the stages of HN infection as 
represented by the viral load and CD4 cell .count and the left ventricle 
ejection fraction, as well as the influence that antiretroviral therapy 
would have on the left ventricle ejection fraction. 
Because cardiac complications are often clinically inapparent or subtle 
in the initial stages, periodic screening of HIV-positive patients by 
electrocardiogram and echocardiogram is important (Millei et aI., 
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1998). The main focus of this research project was the left ventricle 
ejection fraction. The influences of the different variables on the left 
ventricle ejection fraction were measured. The first part of the 
research was done to see what the relationship was between the CD4 
cell count and the left ventricle ejection fraction, and then the 
relationship between the viral load and the left ventricle ejection 
fraction. The second part of the research focused on those patients 
who had a below normal left ventricle ejection fraction (~52%). Here 
the researcher wanted to find cut-off points for the CD4 cell count 
and/or the viral load, where the below normal left ventricle ejection 
fraction occurred most frequently. As subdivisions of the above 
mentioned two main parts of the research, the researcher examined 
the influence of antiretroviral therapy on each. 
The main purpose of this research was to find out more about 
HIV/AIDS, since this devastating disease has a great impact on 
society and there are still so many unanswered questions. Another 
purpose was to emphasize the importa~ce of a good, thorough 
clinical examination of all HIV/AIDS patients by a physician, and the 
use of an echocardiogram in evaluating the cardiac status of a patient 
with HIV/AIDS, especially in the advanced stage. 
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2.1. Virological and Immunological Events 
Following infection by the HI Virus, the virus is transmitted across 
mucocutaneous membranes. HIV rapidly binds to specialized cells of 
the macrophage type, known as Langerhan's cells, which transport 
the virus to regional lymph nodes. This process is probably 
accomplished within a matter of days. Within the lymphoid tissue, 
massive replication of HIV occurs, leading to intensive viraemia and 
widespread dissemination of the virus. During this phase, some 50% 
of individuals may manifest the clinical signs of the Acute Retroviral 
Syndrome (Miller, 2000). 
Within 6 - B weeks, the immune system mounts an aggressive 
response that includes cytotoxic T-cell activity (causing elevation of 
the peripheral blood COB cell count), antibody evolution (which 
results in seroconversion in the ELISA and Western Blot test) and 
cytokine production. In concert, these substantially reduce the level 
of HIV replication and reduce the level of, viraemia. By sixth months 
after infection, viraemia stabilizes at a constant level or "set pOint". 
The quantity of viral RNA measured in the blood after this set pOint 
has been achieved, is known as the "viral load". The viral load is one 
of the two most important prognostic measurements that are 
regularly monitored in the management of people with HIV infection 
(Miller, 2000). 
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During the initial periods of intense viraemia, HIV causes significant 
depletion of CD4 cells. As viraemia is brought under control by the 
host's immune system the CD4 count usually increases, but rarely 
returns to normal levels. Once the set point has been achieved, there 
is a steady decline in CD4 cells at a rate proportional to the viral load, 
i.e. high viral loads result in more rapid loss of the CD4 cells and vice 
versa. On average, without treatment, the CD4 cell count drops at a 
rate of between 50 - 80 cells/ml/year (Miller, 2000). Over a mean of 
8 - 10 years it reaches a low point of <200 cells/ml. A CD4 cell count 
of <200 cells/ml is indicative of severe immunological depletion; this 
is the time when the host is most susceptible to the onset of the 
severe life-threatening opportunistic infections and tumours which 
define the individual as having AIDS. The CD4 cell count is the second 
of the two most important monitoring tests used in the management 
of persons with HIV infection (Miller, 2000). 
Complications may occur as a direct result of HIV itself, or as a 
consequence of the immunosuppressio~ induced by the virus. 
Illnesses related to HIV itself may occur at any CD4 cell count. Once 
the CD4 cell count declines below 200 cells/ml the complications 
regarded as "AIDS-defining" are most prone to occur (Miller, 2(00). 
The course of HIV infection without treatment averages about 10 
years from the time of infection to the onset of AIDS-defining 
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diseases. In some instances, however, people may lose CD4 cells at 
an accelerated rate, achieving levels of <200 cells/ml within 2 - 4 
years; such individuals are termed "rapid progressors". Conversely, 
there are people in whom the CD4 count remains above 500 cells/ml 
for over 8 years in the absence of treatment; these people are 
termed "non-progressors". These variations in the course of HIV 
infection may be due to several factors; pre-eminent amongst these 
is the viral load (Miller, 2000). 
There is a strong correlation between the viral load, as measured by 
HIV RNA levels, and rates of clinical progression. In general, 
individuals with a viral load of <5 000 RNA copies/ml tend to survive 
beyond 10 years without antiretroviral therapy and have an 
associated CD4 cell loss of <50 cellsfyear (Miller, 2000). Between 5 -
7% of HIV infected individuals fall into this category. Over 80% of 
HIV-infected persons have viral loads between 20 000 - 80 000 RNA 
copies/ml and - without treatment - remain well for 8 - 10 years 
after infection. They experience an avera~e CD4 cell loss of 50 - 80 
cellsfyear and are termed "average progressors". Up to 10% of HIV-
positive persons have viral loads of >100 000 RNA copies/ml; they 
tend to progress to AIDS within 2 - 4 years and are termed, "rapid 
progressors"; the annual decline in CD4 cells exceeds 80 cellsfyear in 
this group (Miller, 2000) 
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Reducing the viral load to those levels seen in non-progressors is the 
general goal of HIV therapy. This is associated with a substantial 
alteration in the natural history of HIV infection and results in the 
majority of individuals remaining clinically well for prolonged periods 
of time (Miller, 2000). 
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2.2. Cardiomyopathy, Antiretroviral Therapy and 
HIV/AIOS. 
There is an increased prevalence of cardiomyopathies in patients with 
the acquired immunodeficiency syndrome (AIDS). Dilated 
cardiomyopathy is strongly associated with a CD4 cell count of < 100 
cells/ml, in contrast with the other forms of cardiac dysfunction 
(Currie et a/., 1998). Echocardiographic evidence of lett ventricular 
dysfunction is more common in patients who are the furthest along in 
the course of HIV disease. Individual reports of one to five cases of 
patients with either dilated lett ventricle, hypokinetic lett ventricle or 
both have been reported frequently enough to require explanation. 
Furthermore, the frequent occurrence of cardiomyopathy in children 
who have HIV/AIDS, further suggests a relationship between HIV 
disease and cardiomyopathy (Schlant & Alexander, 1994). Lipshultz et 
a/. (1998) reported that the degree of depression of LVEF correlates 
with the extent of immune dysfunction at base line but not in the long 
term, suggesting that the CD4 cell count may not be a useful 
surrogate marker of HIV-associated lett ventricular dysfunction. 
HIV infection is increasingly recognised as an important ca.use of 
dilated cardiomyopathy. During a study compiled by Barbaro et a/. in 
1998 with a mean follow-up period of 60±S.3 months, an 
echocardiographic diagnosis of dilated cardiomyopathy was made in 
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76 patients (8%) with a mean annual incidence rate of 15.9 cases per 
1 000 patients (Barbaro, 1998b). According to a study published in 
the Hivdent in 1998, clinical cardiomyopahty was seen in 1 to 4% of 
AIDS patients, with patients frequently asymptomatic (Hivdent, 
1998). Ince (1999) also found that 8% of the cohort study they 
compiled had dilated cardiomyopathy and that the greatest incidence 
of dilated cardiomyopathy was in those with depressed CD4 cell 
counts; in particularly in those with CD4 cell counts <300 cells/ml. In 
a review written by Millei et a/. (1998) they described a few different 
prevalences. During one of the studies (Anderson and Virmani, 1990) 
that Millei et a/. (1998) reviewed, cardiovascular disease occurred in 
approximately 6.5 - 6.8% of HIV infected persons. When cardiac 
dysfunction does develop, the signs and symptoms are often 
misinterpreted as being the result of non-cardiac causes (pulmonary 
infection or respiratory failure) that can mimic heart failure (Millei et 
aI., 1998). In another study (Hakim et a/., 1996) reviewed by Millei et 
a!. (1998), which was a prospective survey of 157 acutely ill HIV-
positive patients in a hospital in Zimbabw~, they found that the most 
common echocardiographic abnormalities were left ventricular 
dysfunction with a prevalence of 22% (Millei et a!., 1998). Some 
other studies (De Castro et a!., 1992) reviewed by Millei et a!. ' (1998) 
found that the echocardiographic findings of dilated cardiomyopathy 
have been reported in 30 - 40% of patients with AIDS and in another 
study (Longo Mbenza et a/., 1995) it was found in 16.9% of patients. 
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Dilated cardiomyopathy occurs late in the course of HIV infection and 
is usually associated with a significantly reduced CD4 cell count and 
with symptoms and signs that are attributed to other disease 
processes. Millei et al. (1998) concluded that left ventricular 
dysfunction appears to be increased in patients with low CD4 cell 
counts, although other clinical markers of susceptibility have not yet 
been well defined. In this connection, echocardiographic examination 
seems advisable every 6 months. Murphy (1999) found, in a study 
conducted in Italy in 1997, that 25% of cardiac diseases in HIV 
patients showed dilated cardiomyopathy and reversible hypokinesia. 
Another study in Italy (Lipshultz, 1998) published in October 1998 
showed that 8% of HIV / AIDS patients developed dilated 
cardiomyopathy especially when the CD4 cell count was <400 cells/ml 
(Murphy, 1999). Rerkpattanapipat et at. (2000) found that the 
prevalence of dilated cardiomyopathy ranges from 10 - 30% in 
echocardiogram and autopsy studies. Patients with severe 
symptomatic heart failure usually had a low CD4 cell count. 
Rerkpattanapipat et at. (2000) emph~sised that Coudray and 
colleagues demonstrated in 1995 that left ventricular impairment 
could occur in the early stages of HIV infection. Although the 
prevalence of dilated cardiomyopathy is higher in HIV infected 
patients with low CD4 cell counts, there was no association between 
the progression of left ventricular dysfunction and the rate of CD4 cell 
count decline (Rerkpattanapipat et aI., 2000). Putting together the 
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prevalence rates of dilated cardiomyopathy among HIV infected 
patients from the different authors (Currie et al., 1998; Schlant & 
Alexander, 1994; Lipshultz, 1998; Barbaro et al., 1998b; Hivdent, 
1998; Millei et al, 1998; Murphy, 1999; Rerkpattanapipat et al, 
2000; Pugliese et al, 2000; Acierno, 1989; Warkentin, 1998; Yunis 
and Stone, 1998), it appears that the rates range from as little as 1% 
to as much as 40% in some studies. Most of the studies done agreed 
that the prevalence of cardiomyopathy in HIV/AIDS patients was 
particularly high in those with a low CD4 cell count, mostly with a 
CD4 cell count of less than 300 cells/ml. 
Clinical evidence of cardiac disease is usually overshadowed by 
manifestations in other organs, primarily the brain and lungs. As a 
consequence, the number of patients with AIDS with cardiac 
involvement at autopsy greatly exceeds the number with significant 
cardiac disease during life. Cardiac abnormalities are found at autopsy 
in two-thirds of patients with AIDS (Millei et al, 1998). The heart is 
often the unrecognized target of AIDS ass?ciated lesions even in the 
initial phase of the AIDS outbreak (1981 - 1989) (Millei et al, 1998). 
Although cardiac disease can occur at any stage of HIV infection, 
cardiac morbidity and mortality are more common in advanced 'stages 
(Millei et al, 1998). A study conducted in Italy in August 1998 
showed that out of 440 AIDS autopsies, 82 had cardiac involvement, 
of which 12 had dilated cardiomyopathy (Murphy, 1999). Most of the 
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authors agreed that the number of cardiomyopathies found at 
autopsies were more than those found during life. The most common 
reason for this finding is that the medical field is still very unaware of 
the fact that cardiac dysfunction occurs in HIV/AIDS patients. 
Treatment with the antiretroviral drug zidovudine has been linked to 
the development of dilated cardiomyopathy (Barbaro et a/., 1998b; 
Ince, 1999), but Barbaro et a/., 1998b) felt in the end that the 
difference observed in the incidence of dilated cardiomyopathy 
among the risk groups was influenced more by the extent of 
immunodeficiency than by the type of antiretroviral therapy (Barbaro, 
1998b). Rerkpattanapipat et a/. (2000) also found cardiac dysfunction 
in adults and children treated with zidovudine (Rerkpattanapipat et 
a/., 2000). In contrast with the findings by Ince et a/. (1999), Barbaro 
(1998b) and Rerkpattanapipat et a/. (2000), a study done by Lipshultz 
(1998) indicated that zidovudine neither worsened nor ameliorated 
progressive cardiac changes in HIV infected patients (Lipshultz, 
1998). Highly active antiretroviral therapY ,(henceforth referred to as 
HAART) does dramatically decrease the incidence of cardiac 
involvement in patients with HIV infection, in comparison with 
patients who were only treated with one nucleoside reverse 
transcriptse inhibitor (henceforth referred to as NRTI). In patients 
treated with NRTI, 8.1% had dilated cardiomyopathy compared to 
1.8% of patients treated with HAART (Pugliese et a/., 2000). 
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To conclude, some of the medical studies (Barbaro, 1998b; 
Rerkpattanapipat et aI., 2000; Ince et aI., 1999; Lipshultz, 1998, 
Pugliese et aI., 2000) found that zidovudine was associated with a 
high incidence of cardiomyopathies in HIV/AIDS patients, while others 
disagree with this statement, but as Barbaro (1998b) stated, in the 
end the difference observed in the incidence of dilated 
cardiomyopathy among the risk groups was influenced more by the 
extent of immunodeficiency than by the type of antiretroviral therapy 
used. 
Barbaro et al. (1998b) concluded that dilated cardiomyopathy may be 
related either to a direct action of HIV on the myocardial tissue or to 
an autoimmune process induced by HIV. 
The HIV-1 genome has been demonstrated within myocytes at 
autopsy and biopsy tissue from patients with congestive 
cardiomyopathy, suggesting a direct cytopathic effect by the virus. 
Nevertheless, the pathogenesis of the heart; muscle disease in AIDS is 
still unclear (Barbaro, 1999a). 
The clinical manifestations of AIDS-associated dilated cardiomyopathy 
are similar to those of dilated cardiomyopathy of any cause. The 
echocardiogram is most useful in detecting global hypokinesia with 
decreased ejection fraction and dilation of the various cardiac 
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chambers, with abnormal left: ventricular end-diastolic and end-
systolic dimensions (Acierno, 1989). 
Treatment for dilated cardiomyopathy is the same whether or not 
AIDS is involved (Warkentin, 1998). HIV related cardiomyopathy and 
associated congestive heart failure might respond to standard 
management, including inotropic agents, diuretics, vasodilators and 
angiotensin converting enzyme inhibitors (Yunis et aI., 1998). 
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2.3. Antiretroviral Therapy. 
2.3.1. Mode of Action of Antiretroviral Agents 
HI Virus 
($).~ 
NRllswork 
here 
Protease inhibitors 
work here 
Figure 2.1: HIV replication and sites of work of antiretroviral drugs. 
(Van Dyk, 2001). 
Stages of HIV replication (see figure 2.1): 
1. HIV enters CD4 cell . 
2. HIV is a retrovirus, meaning that its genetic information is 
stored on a single stranded RNA instead of double stranded 
DNA found in most organisms. To replicate, HIV uses an 
enzyme known as reverse transcriptase to convert its RNA to 
DNA. 
3. HIV DNA enters the nucleus of the CD4 cell and inserts itself 
into the cell's DNA. HIV DNA then instructs the cell to make 
many copies of the original virus. 
4. The proteins required for viral assembly are translated. 
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5. New virus particles form and leave, ready to infect other CD4 
cells (Van Dyk, 2001). 
Drugs currently available attempt to block viral replication by 
inhibiting either reverse transcriptase or the HIV protease enzymes. 
Those that inhibit reverse transcriptase fall into two classes: 
Nucleoside reverse transcriptase inhibitors (henceforth referred to as 
NRTI) and non-nucleoside reverse transcriptase inhibitors (henceforth 
referred to as NNRTI). These drugs forestall genetic integration of the 
virus. NRTIs resemble the natural nucleoside building blocks of HIV 
DNA so that when the reverse transcriptase tries to add the drug to a 
developing strand of HIV DNA, it cannot be completed (Anderson et 
a/., 2000). The resulting DNA is incomplete and cannot create a new 
virus (WHO, 2003). NRTIs need to be activated first by 
phosphorylation (Anderson et a/., 2000). 
NNRTI act in stopping HIV production by binding directly onto reverse 
transcriptase (non-competitively) and pre.venting the conversion of 
RNA to DNA (WHO, 2003). 
Protease inhibitors (henceforth referred to as PI) act at a later stage 
and interfere with a viral enzyme, HIV protease, which cleaves viral 
polyproteins into functional end products. This prevents the formation 
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of mature infectious virus and results in the release of immature non-
infectious viral particles (Anderson et aI., 1998; WHO, 2003). 
Hydroxyurea is indicated in the treatment of certain malignancies and 
in sickle cell anemia. It has been used investigationally for the 
treatment of HIV. Hydroxyurea does not have direct antiretroviral 
activity; rather, it inhibits the cellular enzyme ribonucleotide 
reductase, resulting in reduced intracellular levels of deoxynucleoside 
triphosphates (henceforth referred to as dNTPs) that are necessary 
for DNA synthesis. Depletion of the dNTP pool results in arrest of the 
cell cycle in the G1 phase prior to DNA synthesis; in an HIV-infected 
cell, incomplete reverse transcription of the viral genome also results 
from depletion of the dNTP pool. Hydroxyurea also induces the 
activity of cellular kinases that phosphorylate nucleoside analogue 
reverse transcriptase inhibitors, potentially further enhancing their 
antiretroviral activity (Fauci et aI., 1998). Currently, hydroxyurea is no 
longer in use in the treatment of HIVjAIDS. 
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2.3.2. Classification of Antiretroviral Therapy 
Reverse 
T ransaiplase 
Inlibitors 
(RTIs) 
I Arlietrovirallt'frapy I 
I 
I 
Protease 
Inhiitors 
(Pis) 
Steenkamp 20 
OIlier 
Ntx:IeosKie 
Reverse 
Transaiplase 
Inhibitors (NRTl) 
Non-NOOeosKIe 
Reverse 
Transaiplase 
Inlibitors (NNRTI) 
I- Saquilll~r (Rirto-Vase®, Invi-Rase®) L Hydroxyurea (Hydrea®) 
I- RitoIIlvir (Norvir@) 
r- Indlll~r (COOIar®) 
r- Nerllilvir (Wa-f.ept®) 
'- LO~lIlvir/Ritolll~r (Ka~a®) 
r- Zrlmdne (Retrovir®/AZT®) r- Nevirapine (Viramune®) 
r- Didaoosine (VKlex®) L... Efa~renz (stocrir®) 
r- Zakitabine (HMd®) 
r- stavtrlne (ZerR®) 
- Lamivudine (JT(@) 
- LamMxllne+ZiX>vi.dlne (Combivlr®) 
Figure 2.2: Classification of antiretroviral therapy. (Miller, 2002; WHO, 
2002) 
In accordance with WHO and UNAIDS recommendations, these 
guidelines endorse the use of NRTIs and NNRTIs as first-line therapy. 
For initiation of ART therapy two NRTIs and an NNRTI (one drug from 
Category I, one drug from Category II, and one drug from Category 
IV) are recommended. If the viral load is <55 000 a third, NRTI 
(Category III) may be considered as part of a triple NRTI regimen 
(Miller, 2002; Montaner et aI., 1998). 
T.b!. 21 G·d r ~ th f ft· Ith a e . UI e Ines or e use 0 an Ire rovlra erapy. . . 
Category Category Category Category Category V 
I II III IV 
Stavudine Didanosine Abacavir Nevirapine Nelfinavir 
Zidovudine Zalcitabine Efavirenz Indinavir 
Lamivudine Ritonavir 
Saquinavir 
LODinavir/Ritonavir 
(Miller, 2002; WHO, 2002) 
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2.3.3. Goals of Antiretroviral Treatment. 
The primary goals of antiretroviral therapy are: (Miller, 2002) 
¢ To prolong life expectancy. 
¢ To improve quality of life. 
To achieve these primary goals, one would aim to do the 
following: 
1. Maximal and durable suppression of viral load. 
2. Restoration and/or preservation of immunological 
function. 
3. To prevent the development of opportunistic infections 
and other AIDS related conditions. 
4. Reduction of HN related morbidity and mortality. 
Once the decision has been made to initiate ART, the goal is 
maximum viral suppression for as long as possible (Fauci et aI., 1998; 
Anderson et aI., 1998). This is achieved by suppressing viral 
replication as intensely as possible for as long as possible by using 
tolerable and sustainable treatment for an indefinite period of time. 
By doing so, the impact of HIV on the immune system may be 
minimized and the morbidity and mortality associated with HIV 
infection can be improved. Effective therapy has been shown to 
reduce the number of new cells infected by HIV and to impede the 
ability of the virus to evolve drug resistance (Miller, 2002; Montaner 
et aI., 1998; WHO, 2002). 
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2.3.4. Initiation of Antiretroviral Therapy. 
Treatment . should be offered to all patients with the acute HIV 
syndrome, those within six months of seroconversion and all patients 
with symptoms ascribed to HIV infection (Fauci et a/., 1998). 
The latest South African guidelines for the treatment of HIV infection 
recommend starting antiretroviral therapy at CD4 cell counts of 200 
cells/ml or below or for patients with manifestations of opportunistic 
infections (Southern African HIV Clinicians Society, 2002). 
According to the current published international guidelines, the 
following broad criteria guide the selection of patients for initiation of 
therapy: (WHO, 2002) 
¢ All patients with symptomatic HIV infection regardless of CD4 
cell count and viral load levels. 
¢ All patients with CD4 cell count below.350 cells/ml. 
¢ All patients with a high viral load (>30 000 RNA copies/ml) by 
RT-PCR. 
Current guidelines recommend that treatment be considered for 
patients in the intermediate range, i.e. plasma viral load between 10 
000 - 30 000 RNA copies/ml (RT-PCR) and CD4 cell counts between 
350 and 500 cells/ml (WHO, 2002). 
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Treatment of asymptomatic patients, with CD4 cell counts above 500 
cells/ml, is generally deferred as long as the probability of significant 
immune system damage and of clinical progression of HIV infection 
remains low (WHO, 2002). 
Antiretroviral therapy should be deferred until patients are prepared 
to commit themselves to long-term treatment and to maintaining 
good adherence to the therapy. All infected individuals, including 
those on effective ART, should be viewed as potentially infectious. 
Adequate counselling about safer sex practices must be provided to 
encourage prevention of new infections and re-infection (Miller, 2002; 
WHO,2002). 
blo 22 G d I fi h f I h Ta e . ui e ines or t e initiation 0 antiretrovira t erapy. . . 
Symptomatic Patients Treatment 
Presence of HIV related Treatment Recommended 
symptoms, current or previous 
HIV associated disease. * 
Primary Infection. ** Treatment Recommended 
Asymptomatic Patients Treatment 
CD4 cell count <200 cells/ml Treatment Recommended 
CD4 cell count 200 - 350 cells/ml Monitor CD4 cell count and 
commence treatment if the CD4 
annual decline is in excess of the 
expected 20 - 80 cellsfyear, or if 
the CD4 cell count approaches 
200. 
CD4 cell count >350 cells/ml Defer Treatment 
• T11ese include AIDS definmg illnesses (except tuberculOSfS), unexplamed weight loss > 10% of body 
weight unexplained diarrhoea > 1 month, oral candidiasis or oral hairy leukoplakia. 
** Primary infection: HAART started ear1y in primary infection leads to viral suppression which appears 
to maintain HIV spedfic immunity in a significant proportion of cases who become slow progressors with 
a low viral load after discontinuing HAART. The dUration of treatment is uncertain at the present time. 
(Miller, 2002; WHO, 2002). 
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2.3.5. Prescribed Protocols for Antiretroviral Treatment. 
Results of clinical trials to date indicate that the goals may currently 
be best achieved with a potent PI in combination with two NRTIs. 
Another option is the combination of saquinavir plus ritonavir 
combined with one or two NRTIs (Fauci et aI., 1998). 
Maximally suppressive antiretroviral regimens (HAARD should be 
used whenever possible in order to obtain the best clinical results and 
to prevent resistance (Miller, 2002; Montaner et aI., 1998; WHO, 
2002). 
Single drug regimens (monotherapy) should not be used in the 
treatment of HIV infection; however, it continues to play a very 
important role in the prevention of mother to child transmission 
(MTCf) (Miller, 2002; Montaner et aI., 1998; WHO, 2002). 
Dual drug regimens are moderately effective, but are unlikely to 
produce long-term durable benefits in most patients. It is not the 
standard of care, but is considerably better than no therapy and 
should be considered in patients unable to afford HAART. This should 
only be applied to patients who have already developed AIDS. 'In this 
setting, dual therapy is better than no therapy, otherwise resistance 
is a major concern if dual nucleoside therapy is prescribed to 
asymptomatic patients. The efficacy of two drug combinations (dual 
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therapy) is greater than that of monotherapy, potentially achieving a 
1.5 - 1.8 log reduction in viral load. Note that triple combinations are 
the standard of care (Miller, 2002; Montaner et a/., 1998; WHO, 
2002). 
Triple combination of three synergistic antiretroviral agents remains 
the standard of care; substantial reductions in medication prices 
continue to make triple-drug regimens more affordable (Miller, 2002; 
Montaner et a/., 1998; WHO, 2002). 
The approaches to antiretroviral therapy and the design of 
therapeutic regimens have been influenced by the following key 
findings from studies on the pathogenesis of HIV infection: (WHO, 
2002) 
¢ Demonstration that a continuous high level of replication of 
HIV is present from the early stages of infection (at least 1010 
particles are produced and destroyed each day). 
¢ Demonstration that a specific immu~e response to HIV occurs 
in HIV infected subjects during "primary" infection followed by 
a decline after the first months of infection. 
¢ Demonstration that the measured plasma viral load is 
predictive of the sub-sequent risk of disease progression and 
death. 
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¢ Proof that combination ART is not only able to consistently 
suppress HIV replication, but also to induce a significant delay 
in progression to AIDS; this survival benefit is particularly 
marked in previously untreated patients. 
¢ Elucidation of the molecular, functional and clinical impact of 
resistance to antiretroviral drugs. 
2.3.6. Success versus Failure of Antiretroviral Treatment. 
Results of treatment are evaluated primarily with plasma HIV RNA 
levels; these are expected to show a decrease of one log (10 fold) at 
8 weeks and no detectable virus «50 copies/ml) at 4 to 6 months 
after initiation of treatment. Failure of treatment (i.e., plasma HIV 
RNA levels >50 copies/ml) at 4 to 6 months may be ascribed to non-
adherence, inadequate potency of drugs or sub optimal levels of 
antiretroviral agents, resistance and other factors that are poorly 
understood. Patients whose therapy fails should change to at least 
two new agents that are not likely to show cross-resistance with 
drugs given previously (Fauci et aI., 1998). 
Response to ART is monitored clinically and biologically. The most 
important biological measurements are the viral load and CD4 cell 
counts. These measurements correlate with the clinical outcome 
(WHO, 2002). 
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2.3.6.1. Criteria for Treatment Success: 
~ A decline in viral load of at least 1 log from pre-treatment levels 
by 6 - 8 weeks after initiating ART. 
~ A decline in viral load to <50 RNA copies/ml by 24 weeks after 
commencement of therapy. 
~ A sustained viral load of <50 RNA copies/ml is associated with the 
most durable virological benefit (Miller, 2002; Montaner et aI., 
1998). 
2.3.6.2. Criteria Indicative of Treatment Failure: 
~ A sustained increase in viral load >50 RNA copies/ml. 
~ A decline in viral load of less than 1 log within 6 - 8 weeks after 
commencing antiretroviral therapy. 
~ A sustained increase in viral load of >0.6 log from its lowest point 
or a return to 50% of pre-treatment value. 
Inadequate patient adherence to the prescribed regimen remains one 
of the most common reasons for treatment failure. 
Several factors can influence the measurement of HIV viral load. It is 
strongly recommended that the decision to alter therapy should be 
based on the results of at least two consecutive viral load 
measurements performed at least one week apart (Miller, 2002). 
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2.3.7. Viral Resistance to AntiretroYiral Therapy 
Viral resistance to antiretroviral therapy can occur especially when the 
drugs are stopped one at a time, are not taken correctly or omitted. 
It has been suggested that a 20% reduction in adherence to 
treatment may result in an 80% reduction in efficacy (Anderson et 
aI., 1998). 
The high rate of replication that is found throughout the course of 
HIV infection and the variability of HIV, coupled with the relative 
inaccuracy of the enzyme HIV reverse transcriptase, are the main 
reasons for the frequent occurrence of copying errors in the 
transcription of viral genetic information. HIV replicates at the rate of 
around 108 to 1010 virus particles per day - depending on the viral 
load - probably giving rise daily to about 3xlO'3 spontaneous changes 
(mutations) in its genetic sequence. The ultimate size of a viral 
population containing a mutation is probably determined by three 
concurrent factors: the forward mutation frequency, the replicative 
capability of the mutated virus and the "age" of the viral population 
containing the mutation, i.e. how long ago this population was 
generated. With the ongoing production of genetiC variants of HIV 
there is then a continuous selection of the "fittest" virus population 
(WHO, 2002). 
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Sub-optimal ART regimens that allow replication of HIV to continue in 
the presence of antiretroviral drugs encourage the growth of viral 
populations that are carrying a genetic mutation which protects 
against these drugs. It is likely that many of these drug resistance 
mutations already exist before any antiretroviral drug is introduced 
and are further encouraged to proliferate under the selective pressure 
exerted by drug treatment. 
Antiretroviral therapy can minimize the emergence of drug resistance 
in two ways: 
c:> By maximizing and sustaining the suppression of viral 
replication. 
c:> By using drugs where multiple mutations are required before 
resistance can occur (WHO, 2002). 
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2.4. Importance of Echocartiiography to this Study 
Cardiac complications in HIV infection were initially unrecognized or 
recognized late by clinicians because of a lack of awareness of cardiac 
disease in patients with AIDS and the tendency of cardiac disease to 
mimic clinically the far more common respiratory complications (Millei 
et a/., 1998). A review by Millei et a/. (1998) deals with all the cardiac 
manifestations of AIDS and serves to highlight two problems and one 
indication. First of all, there are very few clinical studies. Current 
knowledge is based almost exclusively on echocardiography and 
autopsy studies. Observational or clinical trials based on syndromes of 
heart failure, tamponade and so forth would be useful. Secondly, 
there is very poor information on the impact of treatment. Clinicians 
have assumed that conventional treatment is appropriate for patients 
with heart failure and AIDS; however, there is some anecdotal 
evidence, based upon a low peripheral vascular resistance due to 
sepsis, that these patients tolerate angiotensin-converting enzyme 
inhibitors poorly. Finally, because cardiac complications are often 
clinically inapparent or subtle in the initial stages, periodic screening 
of HIV-positive patients by ECG and echocardiogram is probably 
indicated. The use of routine electrocardiography ' and 
echocardiography for asymptomatic patients with HIV infection is 
controversial (Millei et a/., 1998). Echocardiographic examination is 
more informative and sensitive than electrocardiographic monitoring. 
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Indeed, echocardiography appears to be the most appropriate way to 
detect heart involvement during HIV infection; it allows for early 
diagnosis and thus provides time to find the most suitable way of 
treating cardiac abnormalities, even in the early asymptomatic phase 
of the disease. Prompt recognition and treatment is important 
because palliative therapy with diuretics and vasodilators can be 
worthwhile: mild global left ventricular dysfunction appears to be 
reverSible in many patients and a sub-group progresses to 
symptomatic heart failure without treatment. It appears prudent to 
perform a careful cardiac examination at the time of diagnosis of HIV 
to obtain a baseline functional assessment. An echocardiogram 
should be performed if there are signs of heart disease. One should 
note that the presence of left ventricular dysfunction on a single 
echocardiogram does not necessarily imply a poor prognosis. Ideally, 
viral load assays and CD4 cell counts should be used together with a 
careful clinical examination (Millei et a/., 1998; Warkentin, 1998). 
Millei et a/. (1998) advised that an echocardiogram should be done 
every 6 months. Tavazzi (2002) agrees, that the best diagnostic 
investigation par excellence (also in asymptomatic patients) is the 
echocardiogram. Lipshultz (1998) also recognizes the fact that 
cardiovascular abnormalities are common in HIV-infected patients, 
but are often difficult to diagnose clinically and are frequently 
attributed incorrectly to dysfunction in other organ systems. If these 
abnormalities are diagnosed early through screening, preventive and 
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therapeutic strategies for progressive left ventricular dysfunction can 
be applied (Lipshultz, 1998). HIVjAIDS related cardiomyopathy is a 
diagnostic challenge to which physicians should remain alert (Yunis et 
at, 1998). 
Out of all the different studies and conlusions of the different authors, 
two strong agreements are clear. Firstly, that echocardiography is the 
best test to evaluate the HIVjAIDS patient's cardiac status, and 
secondly, that it is important to do screening echocardiographic tests 
from time to time to evaluate the cardiac status. Here some authors 
felt it is important to do a screening echocardiogram every six 
months, while others felt that it is more important to do the 
echocardiogram screening tests in the advanced stages of AIDS. 
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~1. Pu~oseof~eSwdy 
Acquired immunodeficiency syndrome (AIDS) has become an 
increasingly important health problem worldwide (Acierno, 1989). The 
purpose of this research project is to focus on the influence of 
HIV/AIDS on the LVEF. 
The stage of HIV disease as monitored by the CD4 cell count and the 
viral load is compared with the LVEF. The beneficial effect of ART on 
CD4 cell count and viral load is recognized and accepted. In this study 
the impact of ART on LVEF was evaluated, and the effect of the CD4 
cell count and/or the viral load on the LVEF assessed. This was done 
by comparing the initial consultation together with its blood results 
and LVEF, to the different follow-ups. 
The investigator compiled a pilot study . in 2002 on 302 adult 
HIV/AIDS patients (after inclusion criteria but before exclusion criteria 
had been applied). These patients were .also included (against the 
inclusion and exclusion criteria) in this research project. The pilot 
study showed a direct proportional relationship between the CD4 cell 
count and LVEF and an indirect proportional relationship between the 
viral load and the LVEF. It also showed that the prevalence of an 
LVEF which is below normal «52%), occurred more often when the 
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CD4 cell counts were below 300 cells/ml and/or the viral loads were 
above 100 000 RNA copies/ml. 
If this study gives approximately the same results as the pilot study it 
can bring medical practitioners, healthcare workers and medical aid 
schemes to new insights that can lead - for example - to: 
Medical practitioners carefully considering an echocardiogram from 
time to time to evaluate the LVEF, especially when the viral load is 
above a certain value (according to the pilot study, a value of greater 
than 100 OOOcRNA copies/ml) and/or the CD4 cell count is below a 
certain value (according to the pilot study, a value of less than 300 
cells/ml). This would highlight the importance of cardiovascular 
evaluation in patients with advanced HIV infection. It would have the 
benefit to patients of early detection of cardiac dysfunction and the 
institution of appropriate treatment. 
The impact of antiretroviral therapy is positive in prolonging the lives 
of patients and improving the quality of their lives. By achieving full 
viral suppression, pathological processes that arise because of 
viraemia or immunological deficiency are minimized or eliminated. 
Since cardiac dysfunction is one of these processes, we should see a 
reduction of HIV associated cardiac disease when more and more 
people have access to antiretroviral therapy. 
© Central University of Technology, Free State
Influence of eM, Viral load and ART on L VEF Steenkamp 36 
3.2. Study Objectives 
The first part of the primary objective of this study was to show that 
there is a direct proportional relationship between the CD4 cell count 
and the LVEF and an indirect proportional relationship between the 
viral load and the LVEF. The second part of the primary objective of 
this study was to find a category for the CD4 cell count and viral load 
in which the prevalence of a lower than normal LVEF (:0;52%), was 
higher. 
The first part of the secondary objective was to see what the 
influence of antiretroviral therapy was on the CD4 cell count, viral 
load and the LVEF. The second part of the secondary objective was to 
see what the prevalence was of patients on antiretroviral therapy 
when the LVEF was below normal (:0;52%) and CD4 cell count and 
viral load were within certain ranges 
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Figure 3.1: Summary of study objectives 
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3.3. Hypothesis 
There is a relationship between the viral load, CD4 cell count, and the 
LVEF of HN/AIDS patients, such that when the viral load increases, 
the CD4 count declines and the LVEF decreases, sometimes below the 
normal value. 
Effective antiretroviral therapy in HIV/AIDS patients will lead to a 
decrease in the viral load and an increase in the CD4 cell count. This 
will indirectly lead to an increase in the LVEF. 
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4.1. Study Design 
This is an analytical design that compares the influence of the 
increase or decrease of the CD4 cell count and viral load on the LVEF 
of a patient, and the influence of ART on these variables. The initial 
consultation with its blood results and LVEF were compared to the 
follow-ups. 
4.2. Study Population 
4.2.1. Number of Subjects 
A total of 458 patients were included after the inclusion criteria had 
been applied and the exclusion of other cardiac diseases and those 
who did not give consent were applied. 
4.2.2. Infrastructure 
Dr. M. Makotoko's private practice is very' busy. She is a well-known 
specialist physician and cardiologist with a special interest, and 
wonderful success rate, in the treatment of HIVjAIDS patients. Many 
general practitioners, other physicians and patients refer HIVjAIDS 
patients to dr. Makotoko for treatment and advice. This results in the 
practice receiving patients from throughout South Africa and Lesotho. 
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4.2.3. Inclusion Criteria 
Q HIV.positive patients. 
Q Of South African or Lesotho origin. 
Q Any population group. 
Q Between the ages of 18 - 85 years. 
Q Male and Female. 
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Q Female patients: Both pregnant and non-pregnant women. 
Q Patients who came for consultation to Dr Makotoko's surgery 
between March 1997 and 30 April 2003. 
Q Patients who gave their consent. 
4.2.4. Exclusion Criteria 
Q HIV/AIDS patients who did not have an echocardiogram to 
evaluate the LVEF. 
Q Those who did not give their consent. 
Q Patients with other cardiac diseases that could influence the 
LVEF. 
Q The variables of patients' data, which were compared to each 
other, and were not done within one month of each other, 
were excluded. 
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4.2.5. Justification for In- and Exclusion Criteria 
For ethical reasons patients had to give informed consent before they 
could be included in the study. 
The ethics committee of the University of the Free State reviewed the 
project proposal and gave authorisation. 
All the population groups within South Africa and Lesotho were 
included in order to minimise possible bias on the basis of culture and 
demography. It is also important to include both South African and 
Lesotho citizens, because it is often difficult to distinguish between 
the two countries. A person often has Lesotho citizenship, but works 
and lives in South Africa and vice versa. 
Patients with primary cardiac diseases were excluded as their 
diseases could influence the LVEF. 
Patients who were included had to have · their CD4 cell count, viral 
load and LVEF measurement done within a month of each other for 
accuracy of comparison because all the variables do fluctuate . 
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4.2.6. Subject Identification 
The patients' file numbers - that the practice uses for account 
purposes - were used for identification within the study. These 
numbers were compiled using the first three letters of the surname of 
the person responsible for the account, followed by three numbers 
allocated by the computer account program (MASS®), followed by a 
slash (f), followed by a number indicating which dependent it was. 
For the purpose of publication, this number was linked to a numeric 
value. The numeric value was the only one used during this study. 
This was done for the confidentiality of the patient. Example: 
STE001/1 = nr. 100, the number 100 is the only one used during this 
study. 
4.2.7. Withdrawal Criteria 
Any patient could have withdrawn from this project at any stage. The 
patient's withdrawal would not have been held against him/her and 
his/her consultations and treatment with dr Makotoko would have 
continued as if he/she had never enrolled for the project. 
During the course of this study no drop-outs occurred. 
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4.2.8. Pre-study Clinical Evaluation (Screening) 
¢ Patients received pre-test counselling from the cardiologist 
before an HIV test was performed. 
¢ Upon receipt of the results, patients received post test 
counselling. 
¢ Viral load and CD4 cell count tests were done. 
¢ The nature of the research project was discussed with the 
patient. 
¢ If the patient gave his/her consent, then an echocardiogram, 
for the evaluation of the LVEF, was done. 
¢ The patient and his/her data were weighed against the 
inclusion and exclusion criteria. 
4.2.9. Drop-outs 
There were no drop-outs during the course of this research project. 
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4.4. Biometric Plan 
A statistical analyst from the Department of Biostatistics, University of 
the Free State, was consulted for assistance with the processing of 
the data. Variables were mostly described by frequencies and 
percentages. The relationship between the CD4 cell count and the 
LVEF (see table 5.1) as well as the relationship between the viral load 
and the LVEF (see table 5.2), were assessed by two-by-two tables. 
CD4 cell count and viral load were categorized according to certain 
cut-off points and the percentage cases with LVEF ~52% and LVEF 
>52% were calculated. The percentage cases with below normal 
LVEF for each category of CD4 cell count and viral load were 
calculated and the percentages in the categories were compared with 
the 95% Wilson confidence intervals for the percentage difference 
(Altman et aI., 2001) (see Appendix A, Table A.1 and A.2). Cases 
were categorized as receiving no ART or any combination of ART and 
the percentages of cases with CD4 cell count and viral load below and 
above certain cut-off pOints were calculated. The percentages of 
cases with CD4 cell count and viral load below the cut-off point for 
each ART group were calculated and the percentages in the 
categories were compared with 95% Wilson confidence interVals for 
the percentage difference (Altman et aI., 2001) (see Appendix A, 
Table A.3 and AA). 
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4.5. Practice Registration Form 
All patients attendiflg the practice for the first time completed the 
practice registration form. An example can be seen in Appendix B.2. 
4.6. Subject Information and Informed Consent 
Following pre- and post-test counseling, all HIV positive patients 
would be asked privately if they would be willing to be enrolled in the 
study. The purpose and format of the study as well as the financial 
implications, the consequences, the adverse effects and their right to 
withdraw without any negative effects on them or their doctor-patient 
relationship was explained thoroughly. Those that gave consent 
would then be requested to complete and sign the consent form. The 
patients' doctor, Dr. M. Makotoko, did all of this, before any study-
related activities occurred. The Ethical Committee also approved the 
consent form (ETOVS 33/03). Both the patient information sheet and 
the consent form were available in English, Afrikaans and South 
Sotho (see Appendix B.l). The patients therefore had the choice of 
signing the consent form in anyone of these languages. 
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4.7. Safety Variables 
The research project was very safe. There were no adverse effects 
from the blood tests that were performed. Since the blood tests were 
not done for the sole purpose of the research project, the study itself 
had no adverse effects on the patient. 
The echocardiogram, for the LVEF estimation, is totally harmless and 
no adverse effects were recorded during the course of this research 
project. 
4.8. Premature Discontinuation of the Study 
It did not become necessary to discontinue this research study pre-
maturely. At no stage during the course of the research did the 
researcher or the study leaders feel that any patient's confidentiality 
was compromised or that any unethical procedures had occurred. 
4.9. Accuracy of Data and Data Analysis 
The researcher herself compiled the data from the patients' files. She 
personally double-checked all the data that were written down. This 
could not have been double-checked by someone else, since the 
patients' identities were still known at this stage. 
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All data entered into the computer and all statistical data that were 
counted manually were done and checked by the researcher herself. 
The processed data was also inspected for typing and/or counting 
errors by both Mr. DF Steenkamp (a registered Clinical Technologist 
in Cardiology) and Mrs. EH Thiele (a registered pharmacist). 
The complete research project was read and approved by both the 
study leaders. 
4.10. Good Clinical Practice (GCP) / Quality Assurance 
All clinical work conducted under this research project was subjected 
to the GCP guidelines (Principles of ICH GCP). 
The declaration of Helsinki's basic principle number 3 states that 
research should be conducted only by scientifically qualified persons 
and under the supervision of adequately qualified persons (World 
Medical Association Declaration of Helsinki, 2002). Therefore, the 
whole research project was compiled by a registered Clinical 
Technologist (Registered with the Health Professional Council of 
South Africa, number KT 0006165) under the supervision of two 
study leaders. 
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4.11. Confidentiality 
The confidentiality of this study was of utmost importance. At no time 
during the research could the patient's identity be made known to 
any persons other than those to whom the patient had given his/her 
consent. 
4.12. Ethics Committee 
The study protocol and the informed consent form that were used in 
this study were submitted to the Ethics Committee of the University 
of the Free State and its approval was obtained. The Ethics 
Committee approved the study and supplied an ETOVS number, 
33/03, to the researcher. 
4.13. Apparatus 
The echocardiographic machine that was used for the determination 
of the LVEF was the Toshiba CoreVision® using a 2.SMHz transducer. 
Voigt and Partners - a pathology laboratory situated in Bloemfontein 
- did the CD4 cell count and viral load tests. 
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4.14. Measurement Techniques 
4.14.1. Viral load test 
Performed by: 
Purpose: 
Tests: 
Sensitivity: 
Positive results: 
Voigt and Partners - a pathology laboratory in 
Bloemfontein, South Africa. 
Quantification of HIV. This is the best test for 
staging HIV disease and for monitoring the 
efficacy of treatment. 
PCR (Polymerase Chain Reaction) - Roche 
Amplicor Technique 
Current generation tests measure from 20 - 50 
RNA copies/ml and upwards. 
Patients should be serially monitored using the 
same laboratory technique. Results with PCR are 
about 1,8 times higher than results on the same 
sample using bONA ISH [branched DNA (bONA) 
in situ hybridization (ISH) as a method for 
detection of DNA and mRNA in whole cells 
(Kenny et aI., 2002)]; NASBA [nucleic acid 
sequence based amplification (Smart, 1996)] 
yields results about 10% higher than those 
obtained by PCR. THIS BOOK 
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Precautions: Unexpectedly out-of-range results should be 
confirmed by repeat testing before clinical action 
is taken. 
Appropriate sample: Blood in EDTA (purple-topped) tube (Miller, 
2000a). 
4.14.2. CD4 cell count 
Performed by: 
Purpose: 
Tests: 
Sensitivity: 
Precautions: 
Voigt and Partners - a pathology laboratory in 
Bloemfontein, South Africa. 
To determine the immunological status of the 
patient. It is an essential measure of the risk of 
contracting opportunistic infections and is thus 
used as an indicator for instituting disease 
prophylaxis. 
Two techniques are used: 
(a) Flow cytometry and 
(b) Microcapillary fluorescence. Both yield 
comparable results. 
CD4 cells are measured relatively accurately 
when their number exceeds 50 cells/ml. 
Since CD4 cell counts can fluctuate due to 
extraneous factors, they should always be 
correlated with the CD4 cell % measurement. 
It~NTRAt·UNIVERSiTY OF 
TECHNOLOGY, FREE STATE 
SENTRALE UNIVERSITEIT 
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True increases/decreases in cell % will be 
accompanied by corresponding 
increases/decreases in cell %. Single out-of-
range results should be confirmed by re-testing. 
Appropriate sample: Blood in EDTA (purple-topped) tube (Miller, 
2000a). 
Normal value: Between 510 and 1310 cells/ml (University of the 
Free State, 1997/8). 
4.14.3. Estimation of LVEF 
Performed by. 
Purpose: 
Method: 
A registered clinical technologist. 
To evaluate the left ventricle status of the heart. 
Measurements of the size of the left ventricle and 
the calculation of the LVEF (in %) are part of 
standard echocardiographic procedures. 
The LVEF was measured via echocardiographic 
methods. M-mode and two-dimensional 
echocardiography with colour Doppler and 
continuous wave (CW) Doppler was performed on 
the individuals in a left lateral decubitus position, 
using a Toshiba CoreVision® echocardiography 
machine using a 2.SMHz transducer. Images were 
taken orienting images at the two-dimensional 
mode on the transverse plane of the left ventricle. 
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Sensitivity: 
Results: 
Precautions: 
The most frequently used method is with M-mode 
recording of the left ventricle cavity and wall 
thickness at the level of the mitral chords. The 
Teicholtz formula was used to calculate the LVEF. 
The Teicholtz formula is: 
LVEF = [(end-diastolic - end-systolic)/end-
diastolic] x 100(%) (Echo by Web, 2003). 
The Teicholtz method is very accurate if there is 
no regional wall motion abnormality. 
An immediate result will be calculated right after 
the echocardiogram. Normal values are between 
52% and 75% (Echo by Web, 2003). If the LVEF 
is lower than 52%, the results indicate left 
ventricular dysfunction. 
More than one M-mode recording of the left 
ventricle must always be done. If the LVEF 
measurements differ unexpectedly, the recording 
must be repeated. ,Patients can have poor 
echocardiographic images. In these cases the 
LVEF must be recorded with great care and it 
must be noted that the echocardiogram was 
technically difficult. 
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Time: 
Colour Doppler and CW Doppler must be done to 
exclude any possible cardiac pathology that could 
influence the LVEF. 
A thorough echocardiogram will take 
approximately 15 - 20 minutes. 
4.15. Method of Data Collection and Data Analysis 
The researcher herself did all manual procedures. 
~ Data of all the HIV/AIDS patients who visited the surgery 
from March 1997 up to 30 April 2003 were included. 
~ As far as possible an echocardiogram, to determine the 
LVEF, was done on most of the patients who gave their 
consent. 
~ The LVEFs were done according to the procedure explained 
under 4.14.3. 
~ The CD4 cell count and the viral load tests were done at 
the pathology laboratory according to the procedures 
explained under 4.14.1. and 4.14.2. 
~ After 30 April 2003, all the patients' files that contain all the 
clinical data, were drawn. A complete, detailed list of all the 
LVEF, viral load, CD4 cell count tests, type of ART and 
applicable dates were made. The whole echocardiogram 
report was inspected to see if the patient had any other 
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cardiac diseases that could influence the LVEF. This was 
also noted. All of these procedures were done manually. 
Q All the data were counterbalanced against the exclusion 
and inclusion criteria. This was done manually. All the data 
that met the exclusion criteria were deleted. 
Q All the data were printed out for manual analysis. 
Q The researcher manually counted the total amounts of each 
relationship between the variables. 
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Figure 5.1: Summary of the study population. 
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5.1. General 
A total of 458 patients were included in the research project after the 
exclusion and inclusion criteria had been met. 138 patients did not 
have an LVEF study for reasons discussed under 6.1. They were 
excluded. Ten patients did not have any CD4 cell count or viral load 
tests done, usually due to financial reasons, or because patients 
passed away before these tests could be done, or because they did 
not return after their initial visit for follow-up (see figure 5.1). There 
were 310 patients left. In this group, 165 patients were female and 
145 patients were male, with ages ranging between 20 - 70 years 
(average age was 45 years). 
With reference to figure 5.1, 209 patients had more than one LVEF 
and CD4 cell count that could be compared to each other. To 
accommodate this situation, we referred to each follow-up as a case. 
Therefore, one patient could have multiple cases that were 
compared. 101 patients had only one LVEF. or only one CD4 cell count 
or viral load study. 
© Central University of Technology, Free State
Influence of CD4, Viral load and ART on L VEF Steenkamp 60 
5.2. Comparison between the C04 cell count and the 
LVEF. 
Out of the 118 patients who had CD4 cell counts and LVEF studies to 
compare to each other, 38 patients had two or more CD4 cell counts 
and LVEF studies. This resulted in a total of 178 cases of LVEF studies 
and CD4 cell counts to be compared (see figure 5.1). 
Total number of cases = 118 
4l'<"C".} 
IJThe number of cases that proved the hypothesis correct 
The number of cases that proved the hypothesis wrong 
CThe number of cases that were indeterminate (lor more of the variables stayed constant) 
Figure 5.2: Comparison between the CD4 cell count and the L VEF of 
consecutive follow-ups. 
l VEF: left ventride ejection fraction (Normal value:>52% -75'f6) 
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Table 5.1: Comparison between the CD4 cell count and the L VEF of 
can . Ii. {A secutlVe vow-ups. 
I LVEF 
.... 
.., .,. 
c 
8 .., 29 30 
- .,. 47 68 Qj 
u 
..,. Constant 0 1 e Total 76 99 
""IndIcates an mcrease, + IndIcates a decrease. 
LVEF: Left ventricle ejection fraction (Nannal value:>52% - 75%) 
calculations: 
Constant 
3 
0 
0 
3 
'" Direct proportional relationship between the C04 cell count and LVEF: 
29 + 68: 97.+ 178 x 100: 54.49% 
'" Indirect proportional relationship between the CD4 cell count and LVEF: 
47 + 30: 77 + 178 x 100: 43.26% 
Total 
62 
115 
1 
178 
'" Indeterminate relationship between the C04 cell count and LVEF (one or more of the variables 
stayed constant): 
0+ 1 + 3 + 0 + 0: 4 + 178 x 100 : 2.25% 
This part of the primary objective focused on the relationship between 
the CD4 cell count and the LVEF. Figure 5.1 shows that out of the 118 
patients who had CD4 cell counts and LVEF studies that could be 
compared, 38 patients had more than two CD4 cell counts and LVEF 
studies. To compare the CD4 cell counts and LVEF studies, each CD4 cell 
count and LVEF study that could be compared to each other was referred 
to as a case. There were 178 cases in which the CD4 cell counts and 
LVEF studies could be compared. Figure 5.2 and table 5.1 show that out 
of the 178 cases, 97 cases (54.49%) showed a direct proportional 
relationship between the CD4 cell count and the LVEF. 77 cases 
(43.26%) showed an indirect proportional relationship between the CD4 
cell count and the LVEF. Four cases (2.25%) showed an indeterminate 
relationship between the CD4 cell count and the LVEF, due to one or 
more of the variables that stayed constant and there was no definite 
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. relationship between the variables that stayed constant. In one case the 
CD4 cell count stayed constant at 199 cells/ml, in the other three cases 
the LVEF stayed constant at 58%, 27% and 64% respectively. 
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5.3. Comparison between the viral load and the LVEF 
Out of the 91 patients who had viral load studies and LVEF studies to 
compare to each other, 21 patients had two or more viral load studies 
and LVEF studies. This resulted in a total of 128 cases of LVEF studies 
and viral load studies to be compared (see figure 5.1). 
Total number of cases = 128 
DThe number of cases that prove the hypothesis true CThe number of cases that prove the hypothesis wrong 
OThe number of cases that was indeterminate 
Figure 5.3: Comparison between the viral load and the L VEF of consecutive 
follow-ups. 
LVEF: Left Venlride ejection fraction (Normal value: >52% • 75%) 
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Table 5.2: Comparison between the viral load and the L VEF of consecutive 
fa/low-ups. 
LVEFC%) 
01- If' 
:::: 
~ 01- 20 42 1/1 Q/ 
.~ If' 19 15 
u 
cc ~750000 3 3 z 
.... ~ c 
~ U c :S400 10 14 0 U 
III 
.. 
:; 
Total 52 74 
".Indlcates an Increase, ... Indicates a deuease. 
L VEF: Left Ventride ejection fraction (Nonnal value: >52% - 75%) 
calculations: 
Constant 
0 
2 
0 
0 
2 
¢ Direct proportional relationship between the viral load and L VEF: 
42 + 19 = 61 + 128 x 100 = 47.66% 
¢ Indirect proportional relationship between the viral load and LVEF: 
20 + 15 = 35 + 128 x 100 = 27.34% 
¢ Relationship where one of the variables stayed constant: 
a) Relationships that agree with hypothesis: 
3 + 14 = 17+ 128 x 100 = 13.28% 
b) Relationships that disagree with hypothesis: 
10+3 = 13+ 128 x 100= 10.16% 
Total 
62 
36 
30 
128 
c) Relationships that neither agree nor disagree with hypothesis, i. e. indetenninate relationships: 
2 + 128 x 100 = 1.56% 
This part of the primary objective focused on the relationship between 
the viral load and the LVEF. Figure 5.1 shows that out of the 91 patients 
who had viral load and LVEF studies that could be compared, 21 patients 
had more than two viral load studies and LVEF studies. To compare the 
viral load studies and LVEF studies, each viral load and LVEF study that 
could be compared to each other was referred to as a case. There were 
128 cases in which the viral load and LVEF studies could be compared. 
Table 5.2 show that out of the 128 cases, 61 cases (47.66%) had an 
indirect proportional relationship between the viral load and the LVEF. 35 
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cases (27.34%) showed a direct proportional relationship between the 
viral load and the LVEF. There were 32 cases where one of the variables 
stayed constant. Out of these 32 cases there where 14 cases (10.94%) 
where the viral load stayed constant below 400 RNA copies/ml and the 
LVEF increased. This also shows a positive correlation with the 
hypothesis, since the goal is to keep an HIV/AIDS patient's viral load 
below 400 RNA copies/ml and the hypothesis implied that when the viral 
load is improving (i.e. decreasing), the LVEF will also increase. There 
were three cases (2.34%) that also agreed with the hypothesis, this was 
when the viral load stayed constant above 750 000 RNA copies/ml and 
the LVEF decreased. Out of the total of 32 cases where one of the 
variables stayed constant, there were two relationships that disagreed 
with the hypothesis. One relationship was where the viral load of 10 
cases (7.B1 %) stayed constant below 400 RNA copies/ml, but despite the 
ideal viral load, the LVEF decreased. The other relationship was where 
the viral load of three cases (2.34%) stayed constant above 750 000 
RNA copies/ml, but the LVEF increased. These two relationships do not 
agree with the hypothesis that stated that when the viral load is 
improving (i.e. decreasing, with the ideal value of <400 RNA copies/ml), 
the LVEF would also improve. The last part of the 32 cases where one of 
the variables stayed constant was where two cases (1.56%) had an LVEF 
that stayed constant, while the viral load increased. These two cases 
were indeterminate, because there was no definite relationship between 
the two cases (see figure 5.3). 
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To summarize the findings of figure 5.3 and table 5.2, there were 
60.94% of cases that showed the hypothesis true, while 37.5% showed 
the hypothesis wrong and 1.56% of cases were indeterminate. 
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5.4. Percentage of cases with LVEF <52% in which the 
C04 cellcount was within a specific range. 
Out of the 310 patients who had CD4 cell counts, irrespective of the 
number of cases per patient, 91 patients had a below normal LVEF. 
Sixteen of these patients had more than one case per patient. This 
resulted in 114 cases of patients with CD4 cell counts and LVEF 
studies where the LVEF study was below normal (:552%), and 337 
cases of patients with CD4 cell counts and LVEF studies where the 
LVEF study was within the normal range (>52% - 75%) (see figure 
5.1). This results in a total of 451 cases (see Appendix A, Table A.l, 
Part 1). 
The cut-off points for the CD4 cell counts were 50, 100, 150, 200, 
250, 300, 350, >350 cells/ml. The >350 cells/ml cut-off point (i.e. 0 -
>350) included all the cases defined above (see Appendix A, Table 
A.l, Part 1 - 8). 
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CD4 cell count (cells/ml) cut-off points 
Figure 5.4: Percentage of cases with LVEF below normal (552%), when 
the CD4 cell count was less or equal to specific cut-off points. 
LVEF: Left Ventride ejection fraction (Notmal value: >52% -75%) 
Here the focus was to see what the prevalence of a below normal 
LVEF (:552%) was when the CD4 cell count was at certain cut-off 
points. Out of the 310 patients who had CD4 cell counts and LVEF 
studies, irrespective of the amount of cases per patient, 91 patients 
had an LVEF of below normal (:552%). Sixteen of these patients had 
more than one case per patient. This resulted in 114 cases that could 
be investigated. There were 219 patients with normal LVEF (>52%) 
(see figure 5.1). These 219 patients made up a total of 337 cases 
(see Appendix A, Table A.l, Part 1). Therefore the total number of 
cases in which the CD4 cell count and LVEF (both normal and below 
normal values) could be compared was 451 cases. 
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From figure 504 (see Appendix A, Table A.l, Part 1 - 8) one can see 
that the percentage of cases with a below normal LVEF occurred 
more frequently when the CD4 cell count was :5100 cells/ml. There 
was also a steady decline in the percentage of cases with LVEF below 
normal as the CD4 cell count increased. Of note was the small, but 
unexpected fall in the prevalence of the LVEF below normal (:552%) 
when the CD4 cell count was between 0 - 50 cells/ml. Here we had a 
percentage of cases of 35.87% as opposed to 39.86% when the CD4 
cell count was at the cut-off point of 100 cells/ml. The difference in 
the percentage of cases with below normal LVEF between cases with 
:5100 cells/ml and :550 cells/ml was 3.99%. 
Figure 5.5 shows that the 95% Wilson confidence interval for the 
percentage difference was of statistical importance at all the 
abovementioned cut-off pOints for the CD4 cell count when the LVEF 
was below normal, since the number zero (0) was not included in any 
of 95% confidence intervals at any cut-off pOints during this study. 
The most significant 95% confidence interval was found in the 
percentage of cases in which the CD4 cell count was :5100 cells/ml. 
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(See Appendix A, Table A.1, Part 1 - 8) 
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Figure 5.5: Graphic presentation of the 95% Wilson confidence interval of 
the percentage difference at certain CD4 cell count cut-off pOints, when the 
L VEF was below normal (552%). 
LVEF: Lett Ventride ejection fraction (Normal value: >52% - 75%). 
G : 95% Wilson confidence interval of the percentage difference. 
The difference in the percentages was calwlated by the difference between the percentage of cases with 
below normal L VEF in cases with CD4 cell count less or equal to (:5) the cut-off point, and the CD4 cell 
count larger than the wt-off point. 
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5.5. Percentage of cases with LVEF S52% in which the 
vira//oad was within a specific range. 
Out of the population there were 79 cases of patients with viral load 
studies and lVEF studies in which the lVEF study was below normal 
(:552%), and 286 cases of patients with viral load studies and lVEF 
studies in which the lVEF study was within the normal range (>52% 
- 75%) (see figure 5.1). This resulted in a total of 365 cases (see 
Appendix A, Table A.2, Part 1). 
The ranges in which the viral load (PCR-method) can be measured, 
are between <400 RNA copies/ml (in some cases when the doctor 
requested the ultra sensitive HIV peR viral load test, then the lowest 
limit is <50 RNA copies/ml) up to >750000 RNA copies/ml. The cut-
off pOints in this study were :51 000 (i.e. :5103), 10000 (i.e. 104), 100 
000 (i.e. 105) and 1 000 000 (i.e. 106) . Therefore the lowest value of 
viral load «400 RNA copies/ml or <50 RNA copies/ml in some cases) 
was included in the :51 000 cut-off pOint, and the highest value of 
viral load (~750 000 RNA copies/ml) was included in the cut-off point 
of <1 000000. The cut-off point of <1 000000 will therefore include 
all the above defined cases (i.e. 0 - 1 000 000) (see Appendix A, 
Table A.2, Part 1 - 4). 
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Figure 5.6: Percentage of cases with below normal (552%) LVEF in cases 
with viral load below or equal to the cut-off pOints. 
LVEF: Left ventride ejection ftaction (normal value: >52% -75%) 
Here the focus was to see what the prevalence of a below normal 
LVEF (~52%) was when the viral load was at certain cut-off pOints. 
Out of the 310 patients who had viral load and LVEF studies, 
irrespective of the number of cases per patient, 66 patients had an 
LVEF of below normal (~52%). 10 of these patients had more than 
one case per patient. This resulted in 79 cases that could be 
investigated. There were 244 patients with normal LVEF (>52%). 
These 244 patients had a total of 286 cases. Therefore the total 
number of cases in which the viral load and the LVEF (both normal 
and below normal values) could be compared was 365 (see Appendix 
A, Table A.2, Part 1). 
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(See Appendix A, Table A.2, Part 1 - 4). 
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Figure 5.7: Graphic presentation of the 95% Wilson confidence interval of 
the percentage difference for certain viral load cut-off points in which the 
L VEF was below norma/ (552%). 
The difference in the percentages of cases was calculated by the difference between the percentage of 
cases with below normal LVEF in cases with viral load larger than the cut-off point and the viral load less 
or equal to (5) the cut-off point 
LVEF: Lett ventride ejection fraction (normal value: >52% - 75%) 
G: 95% Wilson confidence interval of the percentage difference. 
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5.6. Influence of ART on the CD4 cell count and the LVEF. 
Out of the 118 patients who had CD4 cell counts and LVEF studies to 
compare to each other, 38 patients had two or more CD4 cell counts 
and LVEF studies. This resulted in a total of 178 cases in which LVEF 
studies and CD4 cell counts could be compared (see Figure 5.1). In 
comparing the cases with one another, the cases to be compared 
were named the 1st case and then the 2nd case. This means that, for 
example, where patient no. 1 had four cases of CD4 cell counts and 
LVEFs to compare, the comparison would be done like this: 
30 January 2001 CD4 = 40, LVEF =50%, No ART 
20 March 2001 CD4 = 100, LVEF = 60%, No ART 
30 July 2001 CD4 = 200, LVEF = 65%, ART 
*1" No ART, 
**200 No ART 
*1st No ART, 
**200 Any 
combination 
ART 
*1" Any 
--'"- combination 
ART, 
30 September 2001 CD4 = 350, LVEF = 68%, ART 
., 1st means the patient was at the first set of variables that was 
compared to a 2'" set of variables on No ART/Any combination of ART. 
.,., 2'" means the patient was at the second set of variables that was 
compared to the first set of variables on No ART/Any combination of 
ART. 
**200 Any 
combination 
ART 
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Table 5.3: Summary of the influence of ART on the CD4 cell 
count and the L VEF. 
Column 1 Column 2 Column 3 Column 4 ColumnS Column 6 
CD4+ CD4+ CD4+ CD4+ CD4(c) CD4+ 
LVEF+ LVEF+ LVEF+ LVEF+ LVEF+ LVEF(c) 
Frequency Frequency Frequency Frequency Frequency Frequency 
Row % Row % Row 010 Row % Row 0/0 Row 0/0 
Column Column Column Column Column Column 
% % % % % % 
a ~ 
*1" NO ART 13 7 12 16 0 0 48 
**2nd No 27.08 14.58 25 33.33 0 
... 
ART 19.11 14.89 41.38 53.33 0 
~ 
0 
IE 
l"NoART 26 13 4 5 0 
2"'Any 54.17 27.08 8.33 10.42 0 
N combination 38.24 27.66 13.79 16.67 0 
! of ART 
l"Any 0 0 2 0 0 
combination 0 0 100 0 0 
'" 
of ART 0 0 6.9 0 0 
~ 2"" NO ART 
~ 
l"Any 29 27 11 9 1 
combination 36.25 33.75 13.75 11.25 1.25 
... 
of ART 42.65 57.45 37.93 30 100 
~ 2"'Any 
0 combination IE 
of ART 
Total 68 47 29 30 1 
l' Indicates an Increase, ., Indicates a decrease, (c) Indicates a vanable that stayed constant 
LVEF: Lett venlTide ejection fraction (NOITTIiII value:>52% -75%) 
ART: Antiretroviral therapy. 
0 
0 
0 48 
0 
0 
0 2 
0 
0 
3 80 
3.75 
100 
3 178 
* 1# means the patient was at the first set of variables that was a;mpared to a ;rt set of variables on No ART/Any 
a;mbination of ART. 
** £II' means the patient was at the second set of variables that was compared to the lirst set of variables on No 
AR71Any rombination of ART 
*/** Ex: On 13 January 2003 the patient's C04 count was 15 and the LVEF was 52% and at this stage the patient 
was on no ART; on 13 June 200J the patient came for a follow-up. His C04 cell rount was 150 and the LVEF was 
60% and the patient was at this stage on any a;mbination of ART. T71eh, the C04 cell count increased, the LVEF 
increased, wilile the patient went from 1# No ART to ;rt anya;mbination of ART. 
© Central University of Technology, Free State
Influence of CD4, Viral load and ART on L VEF Steenkamp 77 
This first part of the secondary objective focused on the influence 
that ART (antiretroviral treatment) had on the CD4 cell count and the 
LVEF (both normal and below normal values). With reference to 
figure 5.1, 209 patients had more than one LVEF and CD4 cell count 
that could be compared to each other. To accommodate this situation 
in which one patient could have more than one follow-up visit to 
compare, we referred to each follow-up that was compared, as a 
case. Therefore, one patient could have multiple cases that were 
compared. 101 patients had only one LVEF or only one CD4 cell count 
or viral load study. Out of the 118 patients who had CD4 cell counts 
and LVEF studies that could be compared, 38 patients had more than 
two CD4 cell counts and LVEF studies. To compare the CD4 cell 
counts and LVEF studies, each CD4 cell count and LVEF study that 
could be compared to each other was referred to as a case. There 
were 178 cases in which the CD4 cell counts and LVEF studies could 
be compared. 
During this discussion, when "1st and 2ndll, are referred to, it means 
that one patient came for more than one follow-up. These follow-ups 
were compared to each other to see if the CD4 cell count, LVEF and 
viral load increased, decreased or stayed constant from one Ilisit to 
another, as well as to see whether the patient was on any 
combination of ART or on no ART from one follow-up to another. 
Therefore, "1 stll referred to the first set of variables that was 
© Central University of Technology, Free State
Influence of CD4, Viral load and ART on L VEF Steenkamp 78 
compared to the following set of variables (at the second follow-up), 
which was named "2nd". 
This part of the results will be discussed as figures 5.8 and 5.9. In 
figure 5.8 the column percentages from table 5.3 were compared to 
one another. This means that the percentage of cases that were on 
any combination of ART or on no ART (rows in table 5.3) from one 
visit to another was compared to different relationships between the 
CD4 cell count and the LVEF (columns in table 5.3). This was done to 
see what the influence was of ART on the total number of cases in 
which there was a specific relationship between the CD4 cell count 
and the LVEF. On the other hand, figure 5.9 shows the horizontal row 
percentages from table 5.3 which were compared to each other. This 
means that the percentage of cases that were on any combination of 
ART or on no ART (rows in table 5.3) from one visit to another was 
compared to different relationships between the CD4 cell count and 
the LVEF (columns in table 5.3). This was done to see what the 
percentage of cases with certain relations~ips between the CD4 cell 
count and the LVEF was when the cases were on any combination of 
ART or on no ART from one visit to another. 
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Figure 5.8: Summary of the influence of ART on the CD4 cell count and 
L VEF from one visit to another (Column percentages - see table 5.3). 
© indicates a variable that stayed constant 
'ftlndicates an increase; ~Indicates a decrease. 
L VEF: Lett ventr/de ejection fraction (Normal value: >52% - 75%) 
pt means the patient was at the first set of vanables that was compared to a rt set of variables on No 
ART/Any combination of ART. 
2" means the patient was at the second set of variables that was compared to the first set of variables 
on No ART/Any combination of ART 
Ex: On 13 January 2003 the patient's eD4 count was 15 and the LVEF was 52% and at this stage the 
patient was on no ART; on 13 June 2003 the patient came for a follow-up. His eD4 cell count was 150 
and the L VEF was 60% and the patient was at this stage on any combination of ART. TlJen the eD4 cell 
count increased, the LVEF increased, while the patient went from 1$1 No ART to ? on any combination 
of ART. 
In figure 5.8 the direct proportional relatio~ship between the CD4 cell 
count and the LVEF was investigated. There were two different direct 
proportional relationships between the CD4 cell count and the LVEF, 
namely when the CD4 cell count increased and the LVEF increased, 
and secondly when the CD4 cell count decreased and the LVEF 
decreased. For these two relationships figure 5.8 shows the following: 
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¢ When the CD4 cell count and the LVEF increased, the 
highest percentage of cases out of this group (total of 68 
cases) were on any combination of ART (42.65%), while 
the second highest percentage of cases occured when the 
patients went from no ART onto any combination of ART 
(38.24%). The percentage of cases that were on no ART 
were only 19.11% of the patients whose CD4 cell count 
and LVEF increased. 
¢ When the CD4 cell count and the LVEF decreased, the 
highest percentage of cases out of this group (total of 29 
cases) were on no ART (41.38%). The second highest point 
was for those patients who were on any combination of 
ART (37.93%). Those cases that were at first on no ART 
and then went onto ART, amounted to 13.79%, while those 
cases that were at first on some sort of combination of ART 
and then stopped (i.e. no ART) only came to 6.90%. 
The indirect proportional relationship between the CD4 cell count and 
the LVEF in figure 5.8 shows two possible relationships, namely the 
CD4 cell count increased, while the LVEF decreased, and CD4 cell 
count decreased while the LVEF increased. The following could be 
seen from figure 5.8: 
¢ When the CD4 cell count increased and the LVEF decreased 
(total of 47 cases), the highest percentage of cases were 
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on any combination of ART (57.45%), while the second 
highest point was for those cases that were at first on no 
ART, but went onto ART before the second follow-up visit 
(27.66%). The two lowest points were for those cases that 
were on no ART (14.89%) and those who were at first on 
ART, but then stopped before the second follow-up visit 
(0%). 
¢ When the CD4 cell count decreased and the LVEF increased 
(total of 30 cases), the highest percentage of cases 
occurred when they were on no ART from one visit to 
another (53.33%), with those who were on any 
combination of ART on both visits making up 30%. The two 
lowest points were for those that were on no ART at first, 
but began ART before the next visit (16.67%), and the 
lowest point was those who were on ART at first, but 
stopped the ART. This was 0%. 
There were cases which showed an i,ndeterminate relationship 
between the CD4 cell count and the LVEF where one of the variables 
stayed constant. Figure 5.8 shows the following: 
¢ When the CD4 cell count stayed constant and the LVEF 
increased (total of one case), the percentage of cases that 
were on ART with both visits, was 100%. It is important to 
note that in this relationship between the CD4 cell count 
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and the LVEF, there was only one case. Therefore the very 
hi.9h peak of 100%. 
¢ When the CD4 cell count decreased, while the LVEF stayed 
constant (total of three cases), the percentage of cases 
that were on any combination of ART, was the highest with 
100%. It is important to note that in this relationship 
between the CD4 cell count and LVEF, there were only 
three cases and all three cases were on ART. Therefore the 
very high peak of 100%. 
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Figure 5.9: Summary of the influence of ART on the CD4 cell count and 
L VEF from one visit to another (Row percentages - see Table 5.3). 
@ Indicates a variable /JJat stayed constant 
.,.Indicates an increase; oI-Indicates a decrease. 
LVEF: Left ventride ejection fraction (Nonnal value:>52% . 75%) 
ART: Antiretroviral /JJerapy 
1" means /JJe patient was at /JJe first set of variables /JJat was compared to a Z'" set of variables on No 
ART/ Any combination of ART. 
?' means the patient was at the second set of variables that was compared to the first set of variables 
on No ART/Any combination of ART 
Ex: On 13 January 2003 /JJe patient's C04 count was 15 and /JJe LVEF was 52% and at /JJis stage /JJe 
patient was on no ART; on 13 June 2003 /JJe patient came for a follow·up. His C04 cell count was 150 
and /JJe L VEF was 60% and /JJe patient was at /JJis stage on any combination of ART. Then the CD4 cell 
count increased, the LVEF increased, while the patient went from 1st No ART to zxt on any combination 
of ART. 
The prevalence of a particular CD4 cell count and LVEF relationships 
out of the total number of cases that were on any combination of 
ART or on no ART from one visit to another, was investigated (see 
figure 5.9). 
© Central University of Technology, Free State
Influence of eM, Viral load and ART on L VEF Steenkamp 84 
The percentage of cases that were on no ART from one follow-up to 
another (total number of cases 48 - dark blue line on figure 5.9) 
shows that the highest percentage of cases were in the group in 
which the CD4 cell count decreased and the LVEF increased 
(33.33%). 27.08% of cases were in the group where the CD4 cell 
count and the LVEF increased; but 25% of cases were in the group in 
which the CD4 cell count decreased and the LVEF increased. The 
cases in the group in which the CD4 cell count increased and the 
LVEF decreased were only 14.58%. 
The percentage of cases that were at first on no ART, but then went 
onto ART before the next follow-up (total number of 48 cases -
orange line on figure 5.9) shows that the highest percentage of cases 
were in the group in which the CD4 cell count and the LVEF increased 
(54.17%). In the groups in which the CD4 cell count and the LVEF 
decreased, and in which the CD4 cell count decreased while the LVEF 
increased, the percentage of cases were very low (8.33% and 
10.42% respectively). There were two groups in which the 
percentage of cases were 0%. One was when the CD4 cell count 
stayed constant while the LVEF increased, and the other one was 
when the CD4 cell count decreased and the LVEF stayed constant. 
The percentage of cases that were at first on ART, but stopped the 
treatment before the next visit (total number of two cases - plum 
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coloured line on figure 5.9) shows only one very high peak of 100% 
in the group in which the CD4 cell count and the LVEF decreased. 
Please note that there were only two cases. Therefore, the very high 
percentage of 100%. 
The percentage of cases which was on any combination of ART at 
both follow-up visits (total number of cases 80 - green line on figure 
5.9) shows that the highest percentage of cases were in the group in 
which the CD4 cell count and the LVEF increased (36.25%), with a 
second high point in the group in which the CD4 cell count increased 
and the LVEF decreased. In all the other groups in which the CD4 cell 
count decreased (CD4 cell count and LVEF decreased, CD4 cell count 
decreased and LVEF increased and CD4 cell count decreased and 
LVEF stayed constant) the percentage of cases was very low 
(13.75%, 11.25% and 3.75% respectively). The lowest point occured 
when the CD4 cell count stayed constant and the LVEF increased 
(1.25%). 
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5.7. Influence of ART on the viral load and the LVEF. 
Out of the 91 patients who had viral load studies and LVEF studies to 
compare to each other, 21 patients had 2 or more viral load studies 
and LVEF studies. This resulted in a total of 128 cases in which LVEF 
studies and viral load studies could be compared (see Figure 5.1). In 
comparing the cases with one another, the cases to be compared 
were named the 1st case and then the 2nd case. This means that, for 
example, where patient no. 1 had four cases of viral load and LVEF to 
compare, the comparison would be done like this: 
30 January 2001 Viral load = >750000, 
20 March 2001 Viral load = >750000, 
LVEF =50%, No AR> 
LVEF = 60%, No AR 
* 1" No ART 
**2"" No AR 
30 July 2001 Viral load = 50000, LVEF = 65%, ART 
30 September 2001 Viral load = <400, LVEF = 68%, ART 
JI: 1st means the patient was at the first set of van"ables that was compared to a r' set of 
variables on No ART/Any combination of ART. 
** r' means the patient was at the second set of variables that was compared to the 
first set of variables on No ART/ Any combination of ART 
1st No ART, 
**2"" Any 
combination 
ART 
1st Any 
combination 
ART, 
**2nd Any 
combination A 
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Table 5.4: Summary of the influence of ART on the viral load and 
the LVEF.  
Column 1 Column 2 Column 3 Column 4 Column 5 Column 6 Column 7 
Viral Viral Viral Viral Viral Viral Viral 
load+ load+ load+ load+ load(c) load(c) load+ 
LVEF+ LVEF+ LVEF+ LVEF+ LVEF+ LVEF+ LVEF(c) 
Frequency Frequency Frequency Frequency Frequency Frequency Frequency 
Row % Row % Row % Row % Row % Row % Row % 
Column% Column% Column% Column% Column% Column% ColumnOJ'o 
Row * 1st No 5 7 3 10 3 2 0 
1 ART 16.67 2333 10 33.33 10 6.67 0 
**2nd 3333 36.84 15 23.81 17.65 1538 0 
No ART (Inalf the (In aD the 
cases the viral cases the waf 
load stayed Ioodstoyed 
constant> 150 constant >750 
000 RNA" 
rooiesImi 
OOORNA., 
cooiesImI 
Row 1st No 3 2 6 21 1 0 0 
2 ART 9.09 6.06 18.18 63.64 3.03 0 0 
2""Any 20 10.53 30 50 5.88 0 0 
combin (InaH the 
ation CilSt!S the viral 
--
ofART constant > 750 
{)()()RNA __ ml) 
Row l"Any 0 1 0 0 0 0 0 
3 combin 0 100 0 0 0 0 0 
ation 0 5.26 0 0 0 0 0 
of ART 
2!idNo 
ART 
Row l"Any 7 9 11 11 13 11 2 
4 combin 10.94 14.06 17.19 17.19 20.31 17.19 
atio" 46.67 47.37 55 26.19 76.47 84.61 
of ART (InaHthe (In JO oot of 
2""Any Cilses the viral the 11 Ci1SeS 
_stayed the viralload 
combin constant <400 
_ronsr..nt 
ation RNA copies/m/) <400 RNA 
of ART copieS/m~· in 
the """" 1 
CilSe it stayed 
constant >750 
=., 
Total 15 19 20 42 17 13 
l' Indicates an Increase, ~ Inchcates a decrease, (c) Indicates a vanable that stayed constant 
LVEF: Left ventride ejection fraction (Nonnal value:>52% - 75%) 
ART: Antiretroviral therapy 
3.13 
100 
2 
* jSt means the patient was at the first set of variables that was compared to a ? set of variables on No ART/Any 
combination of ART. 
*- 2"" means the patient was at the secvnd set of variables that was compared to the first set of variables on No 
ART/Any combination of ART 
'j" Ex: On 13 January 2003 the patient's viral load was 15 and the LVEF was 52% and at this stage the patient 
was on no ART; on 13 June 2003 the patient came for a follow-up. His viral load was 150 and the LVEF was 60% 
and the patient was at this stage on any combination of ART. men the viral/oad increased, the L VEF increased, 
while the patient went from jSL No ART to ;ret on any combination of ART. 
This second part of the secondary objective focused on the influence 
that ART (antiretroviral treatment) had on the viral load and the LVEF 
(both normal and below normal values). With reference to flowchart 
5.1, 209 patients had more than one LVEF and viral load that could 
I 
a ~ 
30 
33 
1 
64 
128 
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be compared to one another. To accommodate this situation in which 
one patient could have more than one follow-up visit to compare, we 
referred to each follow-up that was compared as a case. Therefore, 
one patient could have multiple cases that were compared. 101 
patients had only one LVEF or only one CD4 cell count or viral load 
study. Out of the 91 patients who had viral load studies and LVEF 
studies that could be compared, 21 patients had more than two viral 
load studies and LVEF studies. To compare the viral load studies and 
the LVEF studies, each viral load and LVEF study that could be 
compared to each other was referred to as a case. There were 128 
cases in which the viral load studies and LVEF studies could be 
compared. 
During this discussion when, "1st and 2nd" are referred to, it means 
that one patient came for more than one follow-up. These follow-ups 
were compared to each other to see if the viral load and LVEF 
increased, decreased or stayed constant from one visit to another, as 
well as to see whether the patient was on pny combination of ART or 
on no ART from one follow-up to another. Therefore, "1st" referred to 
the first set of variables that was compared to the following set of 
variables (at the second follow-up), which was named "2nd". 
These results will be presented in two figures, figure 5.10 and figure 
5.11. In figure 5.10 the column percentages from table 5.4 were 
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compared to each other. This means that the percentage of cases 
that were on any combination of ART or on no ART (rows in table 
5.4) from one visit to another was compared to different relationships 
between the viral load and the LVEF (columns in table 5.4). This was 
done to see what the influence was of ART on the total number of 
cases in which there was a specific relationship between the viral load 
and the LVEF. Figure 5.11, on the other hand, shows the horizontal 
row percentages from table 5.4 which were compared to one 
another. This means that the percentage of cases that were on any 
combination of ART or on no ART (rows in table 5.4) from one visit to 
another was compared to different relationships between the viral 
load and the LVEF (columns in table 5.4). This was done to see what 
the percentage of cases with certain relationships between the viral 
load and the LVEF was when the cases were on any combination of 
ART or on no ART from one visit to another. 
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Figure 5.10: Summary of the influence of ART on the viral load and L VEF 
from one visit to another (Column percentages - see Table 5.4). 
© Indicates a variable that stayed cvnstant 
".Indicates an ina-ease; "'Indicates a dea-ease. 
*: Viralload stayed cvnstant ~ 750 000 RNA cvpies,/ml in all the cases. 
# : Viral load stayed cvnstant :5400 RNA cvpies,/ml in all the cases. 
**: Viralload stayed cvnstant ~ 750 000 RNA copies,/ml in 7. 69% of ca~ and :5400 RNA copies/ml in 
76.92% of cases. 
LVEF: Left ventride ejection fraction (Normal value:>52% -75%) 
ART: Antiretroviral therapy 
VL: Viralload (measured in RNA cvpies,/ml) . 
1st means the paaent was at the first set of variables that was compared to a zxt set of variables on No 
ART/Any combination of ART. 
Z'" means the patient was at the secvnd set of vanables that was compared to the first set of variables 
on No ART/ Any cvmbination of ART 
Ex: On 13 January 2003 the patient's viral load was 15 and the LVEF was 52% and at this stage the 
patient was on no ART," on 13 June 2003 Me patient came for a follow-up_ His viral/oad was 150 and the 
L VEF was 60% and the patient was at this stage on any combination of ART. Then the viral load 
ina-eased, the LVEF increased, while the patient went hvm 1" No ART to Z'" on any combination of ART. 
In figure 5.10 the indirect proportional relationship between the viral load 
and the LVEF was two fold, namely when the viral load increased and the 
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LVEF decreased, or when the viral load decreased and the LVEF 
increased. For these two relationships, figure 5.10 shows: 
~ When the viral load increased and the LVEF decreased (total 
number of cases = 19), the highest percentage of cases were on 
any combination of ART (47.37%). The lowest point was for those 
patients who were taking ART, but stopped the treatment before 
the 2nd follow-up (5.26%). In between these two points were 
those that were on no ART (36.84%) and those that were at first 
on no ART, but started with ART before the next follow-up. 
~ When the viral load decreased and the LVEF increased (total 
number of cases = 42), the highest percentage of cases were at 
first on no ART, but started ART before the next visit (50%). The 
second highest point was for those cases that were on any 
combination of ART during both visits (26.19%). Those cases that 
were on no ART were 23.81%. There were no cases (O%) that 
were on ART at first and then stopped the treatment. 
The direct proportional relationship between the viral load and the LVEF 
from figure 5.10 shows two possibilities. First, the viral load and the LVEF 
increased, and secondly, the viral load and the LVEF decreased. For 
these two relationships figure 5.10 shows: 
~ That when the viral load and the LVEF increased (total of 15 
cases), the highest percentage of cases were on any combination 
of ART (46.67%). The second highest point was for those cases 
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that were on no ART (33.33%). 20% of cases were at first on no 
ART, but started with ART before the next visit. There were no 
cases (0%) in which the patients were at first on ART, but 
stopped the treatment before the next visit. 
¢ That when the viral load and LVEF decreased (total of 20 cases), 
the highest point was for those cases that were on ART during 
both visits (55%). The second highest point was for those cases 
that went onto ART before the second follow-up (30%). Only 15% 
of cases were on no ART. There were no (0%) cases in which the 
patients were first on ART and then stopped taking it before the 
next visit. 
The relationships between the viral load and the LVEF where one of the 
variables stayed constant were three different relationships. First, the 
viral load stayed constant and the LVEF increased, secondly the viral load 
stayed constant and the LVEF decreased, and thirdly the viral load 
increased and the LVEF stayed constant. For these three relationships 
figure 5.10 shows that: 
¢ When the viral load stayed constant and the LVEF increased (total 
number of cases = 17), the viral load of 14 cases stayed constant 
below 400 RNA copies/ml, and the viral load of three cases stayed 
constant above 750 000 RNA copies/ml. The highest percentage 
of cases were on any combination of ART during both follow-up 
visits (76.47%). In all of these 76.47% of cases, the viral load 
© Central University of Technology, Free State
Influence of eM, Viral load and ART on L VEF Steenkamp 93 
stayed constant below 400 RNA copies/ml. The second highest 
point occurred in those cases that were on no ART (17.65%). In 
all of these 17.65% of cases, the viral load stayed constant above 
750 000 RNA copies/ml. 5.88% of cases went from no ART onto 
ART before the next follow-up. The viral load of these percentage 
of cases stayed constant above 750 000 RNA copies/ml. Out of 
these findings one could say that the highest point was when the 
the viral load stayed constant below 400 RNA copies/ml, while the 
LVEF increased, and they were on ART from one visit to another. 
This shows a very positive influence of the ART on the viral load, 
because the goal is to keep the viral load below 400 RNA 
copies/ml for as long as possible. 
~ When the viral load stayed constant and the LVEF decreased (total 
number of cases = 13). Out of these thirteen cases, the viral load 
of three cases stayed constant above 750 000 RNA copies/ml and 
the viral load of ten cases stayed constant below 400 RNA 
copies/ml. The highest percentage of cases were on any 
combination of ART from one follow-L1P to the next (84.61%). 
From this 84.61% of cases the viral load of 76.92% cases was 
below 400 RNA copies/ml, and the viral load of 7.69% cases was 
above 750 000 RNA copies/ml. The second highest percentages of 
cases were on no ART (15.38%). All of the viral loads of these 
15.38% cases were above 750 000 RNA copies/ml. There were no 
(0%) cases that went onto ART (that was at first on no ART and 
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then went onto ART before the next visit), or that were on ART 
and then stopped the treatment before the next visit 
~ When the viral load increased and the LVEF stayed constant (total 
number of cases = 2). This was an indeterminate relationship, 
because there was no definite relationship between these two 
cases and the LVEF did not stay constant at the same value in the 
two cases. Both of these cases were on ART from one visit to 
another. Therefore the very high percentage of 100%. 
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Figure 5.11: Summary of the influence of ART on the viral load and the 
L VEF from one visit to another (Row percentages - see Table 5. 4). 
© Indicates a variable that stayed constant 
".Indicates an increase; 4-lndicates a decrease. 
*: Viral load stayed constant ~750 000 RNA copies/ml in all the cases. 
#: Viral load stayed constant 5400 RNA copies/ml in all the cases. 
*': Viral load stayed constant ~ 750 000 RNA copies/ml in 1.56% of ca,*", and 5400 RNA copies/ml in 
15. 63% of cases. 
LVEF: Left ventride ejection fraction (Normal value:>52% · 75%) 
ART: Antiretroviral therapy 
VL: Viral load (measured in RNA copies/ml) 
1<;f means the patient was at the first set of variables that was compared to a ? set of variables on No 
ART/Any combination of ART. 
zId means the patient was at the second set of variables that was compared to the first set of variables 
on No ART/Any combination of ART . 
Ex: On 13 January 2003 the patient's viral load was 15 and the LVEF was 52% and at this stage the 
patient was on no ART; on 13 June 2003 the patient came for a fo/low-up. His viral/oad was 150 and the 
L VEF was 60% and the patient was at this stage on any combination of ART. Then the viral load 
increased, the LVEF increasect while the patient went from 1st No ART to ZV on any combination of ART. 
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The prevalence of certain viral load and LVEF relationships out of the 
total number of cases that were on any combination of ART or on no 
ART from one visit to another was investigated (see figure 5.11). 
The percentage of cases that were on no ART from one follow-up to 
another (total number of cases 30 - blue line on figure 5.11) shows 
that the highest percentage of cases were in the group in which the 
viral load decreased and the LVEF increased (33.33%). The second 
highest point occured when the viral load increased and the LVEF 
decreased (23.33%). Both these highest and second highest points 
show an indirect proportional relationship between the viral load and 
the LVEF. 
The percentage of cases that were at first on no ART, but then went 
onto ART before the next follow-up (total number of 33 cases -
purple line on figure 5.11) shows that the highest percentage of 
cases were in the group where the viral load decreased and the LVEF 
increased (63.64%). The second highest point occured in the group 
where the viral load and the LVEF decreased (18.18%). 
The percentage of cases that were at first on ART, but stopped the 
treatment before the next visit (total number of one case - orange 
line on figure 5.11) shows only one very high peak of 100% in the 
group in which the viral load increased and the LVEF decreased. 
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Please note that there was only one case, therefore, the very high 
percentage of 100%. 
The percentage of cases at both follow-up visits on any combination 
of ART (total number of cases 64 - green line on figure 5.11) shows 
that the highest percentage of cases were in the group in which the 
viral load stayed constant and the LVEF increased (20.31%). The viral 
load of all of these 20.31% of cases stayed constant below 400 RNA 
copies/ml. The second highest pOints were in the groups in which the 
viral load decreased and the LVEF increased, the viral load and LVEF 
decreased, and the viral load stayed constant (the viral load of 10 out 
of the 11 cases, i.e. 15.63% of the 17.19% of cases, stayed constant 
below 400 RNA copies/ml) while the LVEF decreased, all at 17.19% 
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5.8. Percentage of cases on ART versus those on no ART 
at certain CD4 cell count cut-off points and with 
L VEF below normal «52%). 
Out of the population there were 114 cases of patients with CD4 cell 
counts and LVEF studies in which the LVEF study was below normal 
(:552%). Out of these cases 67 were not on ART and 47 were on any 
combination of ART (see figure 5.1 and Appendix A, Table A.3, Part 
1). 
The cut-off points for the CD4 cell count were 50, 100, 150, 200, 250 
300, 350, >350 cells/ml. The >350 cells/ml cut-off pOint (i.e. 0 -
>350) includes all the cases defined above (see Appendix A, Table 
A.3, Part 1 - 8). 
Here the focus was on comparing the percentage of cases with below 
normal LVEF on any combination of ART to those that were on no 
ART when their LVEF was below normal, at particular CD4 cell count 
cut-off points. Out of the 310 patients who had CD4 cell counts and 
LVEF studies, irrespective of the amount of cases per patient, 91 
patients had an LVEF of below normal (:552%). Sixteen of these 
patients had more than one case per patient. This resulted in 114 
cases to be investigated (see figure 5.1). Out of these 114 cases, 67 
cases were not on ART and 47 cases were on any combination of ART 
(see Appendix A, Table A.3, Part 1). 
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The cut-off points for the CD4 cell counts were 50, 100, 150, 200, 
250, 300, 350, >350 cells/ml. The >350 cells/ml cut-off point (Le. 0 -
>350) includes all the cases defined above (see Appendix A, Table 
A.3, Part 1 - 8). 
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Figure: 5.12: Percentage of cases on ART versus those not on ART at 
certain CD4 cell count cut-off paints and with L VEF below normal (552%). 
LVEF: Lett ventricle ejection fraction (Normal value:>52% - 75%) 
ART: Anliretroviral therapy- -
Figure 5.12 shows that the percentage of cases whose LVEF was 
below normal and that were not on any ART was more than those 
who were on ART. The percentages of cases in both groups of cases 
(those who were on ART with LVEF below normal, and those who 
were on no ART with LVEF below normal) increased as the CD4 cell 
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count increased up to the cut-off point of 350 cells/ml, and then both 
decreased steeply when the CD4 cell count reached the >350 cells/ml 
cut-off point. 
Even though figure 5.12 shows that the occurrence of a below normal 
LVEF was less in those cases that were on ART than those that were 
on no ART, figure 5.13 shows an important point. In figure 5.13 one 
can see that the 95% Wilson confidence interval of the difference was 
of no statistical importance at almost all the CD4 cell count cut-off 
pOints, since the number zero was included. The only cut-off point 
that showed any statistical importance was the cut-off point of 250 
cells/ml. At this cut-off point the 95% confidence interval was [0.60% 
; 33.80%]. The lowest point of the confidence interval was still very 
low, although it exceeded zero. The clinical importance of this 
confidence interval is doubtful, but should be considered since the 
upper limit of the 95% confidence interval is high. 
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(See Appendix A, Table A.3, Part 1 - 8). 
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Figure 5.13: Graphic presentation of the 95% Wilson confidence interval of 
the percentage difference between those on ART versus those on no ART; 
when the CD4 cell count was at specific cut-off points and the L VEF below 
normal (552%). 
LVEF: Left ventride ejection fraction (Normal value:> 52% - 75%) 
G: 95% Wilson confidence interval of the percentage difference. 
ART: Antiretroviral therapy 
The difference in the percentages was calculated by the difference between the percentage of cases with 
below normal LVEF in cases with eD4 cell count less or equal Iv (5 ) the cut-off point of those cases that 
WeIC' on no ART and those cases that were on any combination of ART. 
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5.9. Percentage of cases on ART versus those on no ART 
at certai!1 viral load cut-off points and L VEF below 
normal «52%). 
Out of the population there were 79 cases of patients (see Figure 5.1) 
with viral load and LVEF studies in which the LVEF was below normal 
(:552%). Of the 79 cases, 47 were not on ART and 32 were on any 
combination of ART (see Appendix A, Table A.4, Part 1). 
The ranges in which the viral load (PCR-method) can be measured, 
are <400 RNA copies/ml (in some cases when the doctor requested 
the ultra HIV PCR viral load, then the lowest limit is <50 RNA 
copies/ml) up to >750 000 RNA copies/ml. The cut-off points in this 
study were :51 000 (Le. :5103), 10 000 (Le. 104), 100 000 (Le. 105) 
and 1 000 000 (Le. 106). Therefore the lowest value of viral load « 
400 RNA copies/ml or in some cases <50 RNA copies/ml) were 
included in the :51 000 cut-off point, and the highest value of viral 
load (>750 000 RNA copies/ml) was included in the cut-off point of 
<1 000000. The cut-off point of <1 000000 would therefore include 
all the above defined cases (Le. 0 - 1 000 000) (see Appendix A, 
Table A.4, Part 1 - 4). 
Here the focus was on comparing the percentage of cases with below 
normal LVEF on any combination of ART to those who were not on 
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ART when their LVEF was below normal, at certain viral load cut-off 
points. Out of the 310 patients who had viral load and LVEF studies, 
irrespective of the number of cases per patient, 66 patients had an 
LVEF of below normal (::552%). Ten of these patients had more than 
one case per patient. This resulted in 79 cases to be investigated (see 
figure 5.1). Out of these 79 cases, 47 cases were not on ART and 32 
on any combination of ART (see Appendix A, Table A.4, Part 1 - 4). 
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Figure 5.14: Percentage of cases on any combination of ART versus those 
who were on no ART, at certain viral load cut-off points in which the L VEF 
was below normal (552%). 
LVEF: Lett ventride ejection fraction (Normal value:>52% -75%) 
ART: Antiretroviral therapy 
Figure 5.14 shows that the percentage of cases with below normal 
LVEF on ART occurred more frequently than those with below normal 
LVEF that were on no ART, up to the cut-off point of 100 000 RNA 
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copies/ml. When the viral load was > 100 000 RNA copies/ml, there 
was a sudden decrease in the percentage of cases with below normal 
LVEF on ART, to a point that was below those cases who were on no 
ART. There was also a steady increase in the percentage of cases 
with below normal LVEF on no ART, after the cut-off point of 100 000 
RNA copies/mi. This might be due to the fact that when the viral load 
is very high (above 100 000 RNA copies/ml) the patients are usually 
not on ART or they have stopped taking the ART. Out of all 79 cases 
that had an LVEF of below normal and a viral load to compare, 59.5% 
of cases were not on ART, and 40.5% used any combination of ART. 
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Figure 5.15: Graphic presentation of the 95% Wilson confidence interval 
for the percentage difference of cases on no ART versus those on any 
combination of ART at certain viral load cut-off points, in which the L VEF 
was below normal (552%). 
LVEF: Left ventricle ejection fraction (Normal value:>52%· 75%) 
G: 95% Wilson contfdence interval for the percentage difference 
ART: Anliretroviral therapy 
T77e difference in the percentage was calculated by the difference between the percentage of cases with 
below normal LVEF in cases with viral load smaller or equal (:5) to the cut-off point for the cases that 
were on any combination of ART and for the cases that were on no ART. 
The 95% Wilson confidence interval for the percentage difference for 
this part of the secondary objective is shown in figure 5.15. All of the 
95% confidence intervals were of statistical importance, since the 
number zero was not included in anyone of the confidence intervals. 
The highest confidence interval [9.50% ; 60.50%] occurred at the 
cut-off point of 10 000 RNA copies/ml. 
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A total of 458 patients were included in the research project after the 
exclusion and inclusion criteria had been met. 138 patients did not 
have an LVEF study for reasons discussed under 6.1. They were 
excluded. Ten patients did not have any CD4 cell count or viral load 
tests done, usually for financial reasons, or patients passed away 
before these tests could be done, or did not come back for follow-up 
visits after the initial consultation (see figure 5.1). There were 310 
patients left. In this group of patients 165 were female and 145 were 
male, with ages ranging between 20 - 70 years (average age was 45 
years). 
In this research study it was shown that there is a direct proportional 
relationship between the CD4 cell count and the LVEF (see figure 
5.2), and an indirect proportional relationship between the viral load 
and the LVEF (see figure 5.3). The below normal LVEF (:552%) 
occurred most frequently when the CD4 cell count was below 100 
cells/ml (see figure 5.4) - which correlates well with the findings of 
Currie et at. (1998) - and/or the viral loac,1 was above 100 000 RNA 
copies/ml (see figure 5.5), i.e. a very advanced stage of HIV 
infection. Schlant and Alexander (1994) also indicated that 
echocardiographic evidence of left ventricle dysfunction is more 
common in patients who are the furthest along in the course of HIV 
disease. Lipshultz et at. (1998) reported that the degree of depression 
of LVEF correlates with the extent of immune dysfunction at baseline 
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but not in the long term, suggesting that the CD4 cell count may not 
be a useful surrogate marker of HIV-associated left ventricular 
dysfunction. 
Figure 5.4 shows that there was a steady decline in the percentage of 
cases with LVEF below normal as the CD4 cell count increased, but 
there was an unexpected fall in the prevalence of the LVEF being 
below normal (:552%) when the CD4 cell count was between 0 - 50 
cells/ml. Here the percentage of cases was 35.87% as opposed to the 
39.86% when the CD4 cell count was at the cut-off point of 100 
cells/ml. The difference in the percentage of cases with below normal 
LVEF between cases with :5100 cells/ml and :550 cells/ml, was 
3.99%. No clear reason could be found as to why this occurred. This 
prevalence is still unanswered. Ince et at. (1999) also found that the 
greatest incidence of dilated cardiomyopathy was in those with 
depressed CD4 cell counts in particularly in those with CD4 cell counts 
of <300 cells/ml. 
In figure 5.8 the direct proportional relationship between the CD4 cell 
count and the LVEF was investigated. Here there were 2 different 
relationships between the CD4 cell count and the LVEF, namely the 
CD4 cell count increased and the LVEF increased, and secondly the 
CD4 cell count decreased and the LVEF decreased. 
relationships figure 5.8 shows the following: 
For these two 
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¢ When the CD4 cell count and the LVEF increased, the 
highest percentage of cases out of this group (total of 68 
cases) were on any combination of ART (42.65%), while 
the second highest percentage of cases occured when the 
patients went from no ART onto some or other combination 
of ART (38.24%). The percentage of cases that were on no 
ART came to only 19.11% of the patients whose CD4 cell 
count and LVEF increased. 
¢ When the CD4 cell count and the LVEF decreased, the 
highest percentage of cases out of this group (total of 29 
cases) were on no ART (41.38%). The second highest point 
occured in those patients who were on any combination of 
ART (37.93%). Those cases who were at first on no ART 
and then went onto ART, came to 13.79%, while those 
cases who were at first on some sort of combination of ART 
and then stopped it (Le. no ART) amounted to only 6.90%. 
The indirect proportional relationship betw~en the CD4 cell count and 
the LVEF in figure 5.8 shows two possible relationships, namely the 
CD4 cell count increased, while the LVEF decreased, and CD4 cell 
count decreased while the LVEF increased. The following can be seen 
from figure 5.8: 
¢ When the CD4 cell count increased and the LVEF decreased 
(total of 47 cases), the highest percentage of cases were 
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on any combination of ART (57.45%), while the second 
highest point occured in those cases that were at first on 
no ART, but went onto ART before the second follow-up 
visit (27.66%). The two lowest points occurred in those 
cases that were not on ART (14.89%) and those that were 
at first on ART, but then stopped it before the second 
follow-up visit (0%). 
Q When the CD4 cell count decreased and the LVEF increased 
(total of 30 cases), the highest percentage of cases 
occurred when they were on no ART from one visit to 
another (53.33%), with those that were on any 
combination of ART on both visits, second (30%). The two 
lowest points occurred in those that were on no ART at 
first, but began with ART before the next visit (16.67%), 
and the lowest point occurred in those that were on ART at 
first, but stopped the ART. This amounted to 0%. 
In the indeterminate relationship between the CD4 cell count and the 
LVEF one of the variables stayed constant. Figure 5.8 shows the 
following: 
Q When the CD4 cell count stayed constant and the LVEF 
increased (total of one case), the percentage of cases that 
were on ART with both visits, was 100%. It is important to 
note that in this relationship between the CD4 cell count 
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and the LVEF, there was only one case, therefore the very 
high peak of 100%. 
¢ When the CD4 cell count decreased, while the LVEF stayed 
constant (total of three cases), the percentage of cases 
that were on any combination of ART was the highest, with 
100%. It is important to note that in this relationship 
between the CD4 cell count and LVEF, there were only 
three cases and all three cases were on ART, therefore the 
very high peak of 100%. 
In summarizing all the findings from figure 5.8, one can see that in all 
the cases in which the CD4 cell count increased, the highest 
percentage of cases were on any combination of ART. When the CD4 
cell count decreased, the highest percentage of cases were on no 
ART, with exception of those three cases in the group in which the 
CD4 cell count decreased, while the LVEF stayed constant. In the one 
case when the CD4 cell count stayed constant, the highest 
percentage of cases were on any combil')ation of ART during both 
visits. In contrast to this, when the LVEF increased, the highest 
percentage of cases were sometimes on any combination of ART (in 
the group in which the CD4 cell count and the LVEF increased, and in 
the one case in which the CD4 cell count stayed constant and the 
LVEF increased) and sometimes the highest percentage of cases were 
on no ART (in the group in which the CD4 cell count decreased and 
© Central University of Technology, Free State
Influence of CD4, Viral load and ART on L VEF Steenkamp 112 
the LVEF increased). When the LVEF decreased, the highest 
percentage of cases were sometimes those cases that were on any 
combination of ART during both visits (in the group in which the CD4 
cell count increased and the LVEF decreased), and sometimes those 
cases that were on no ART (in the group in which the CD4 cell count 
decreased and the LVEF decreased). Therefore it seems as if the ART 
had a positive effect on the CD4 cell count in such a way that when 
the patients were on ART, the CD4 cell count increased, and when 
the patients were on no ART, the CD4 cell count tended to decrease. 
But no relationship between the LVEF and ART could be shown, Le. 
one could not say that ART caused the LVEF to increase or decrease. 
This brings us back to figure 5.2, which indicates that the CD4 cell 
count and the LVEF had a direct proportional relationship. Therefore, 
one could assume that if the ART had a positive effect on the CD4 cell 
count (Le. the CD4 cell count increased when the patients were on 
ART), the CD4 cell count that increased would have an increasing 
effect on the LVEF, although the ART did not have a direct effect on 
the LVEF. • 
In summarizing the findings from figure 5.9, one can see that in all 
the groups in which the CD4 cell count increased, the highest 
percentage of cases were on ART or went onto ART (no ART at first, 
but before the 2nd follow-up, they started with ART). In the groups in 
which the CD4 cell count decreased, the highest percentage of cases 
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were on no ART. Therefore it seemed as if the ART had a positive 
effect (to increase the CD4 cell count) on the CD4 cell counts. On the 
other hand, in the groups in which the LVEF increased, some of the 
highest percentage of cases were on ART, some went onto ART, and 
others were on no ART. The same was seen when the LVEF 
decreased. Some of the highest percentage of cases were on ART, 
while other high percentages were on no ART. Therefore it did not 
seem as if the ART resulted in the LVEF increasing or decreasing. 
From figure 5.2 it was seen that there was a direct proportional 
relationship between the CD4 cell count and the LVEF. Thus, if the 
ART had a positive effect on the CD4 cell count, and the CD4 cell 
count increased, then one could expect that the LVEF would also 
increase, rather than decrease. 
The findings of figure 5.8 and 5.9 correlates with the findings of 
Pugliese et a/. (2000) who said that HAART does dramatically 
decrease the incidence of cardiac involvement in patients with HIV 
infection as opposed to patients only treate9 with one NRTI. 
In figure 5.10 the indirect proportional relationship between the viral 
load and the LVEF was twofold; namely when the viral load increased 
and the LVEF decreased; or when the viral load decreased and the 
LVEF increased. For these two relationships, figure 5.10 shows that: 
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¢ When the viral load increased and the LVEF decreased (total 
number of cases = 19), the highest percentage of cases were 
on any combination of ART (47.37%). The lowest point 
occurred when those that were taking ART stopped the 
treatment before the 2nd follow-up (5.26%). In between these 
two points were those who were on no ART (36.84%) and 
those who were at first on no ART, but started with ART 
before the next follow-up. 
¢ When the viral load decreased and the LVEF increased (total 
number of cases = 42), the highest percentage of cases were 
at first on no ART, but started with ART before the next visit 
(50%). The second highest point occurred in those cases that 
were on any combination of ART during both visits (26.19%). 
23.81% of cases were on no ART. There were no cases (O%) 
that were on ART at first and then stopped the treatment. 
The direct proportional relationship between the viral load and the 
LVEF from figure 5.10 shows two possible relationships. First, the viral 
load and the LVEF increased, and secondly, the viral load and the 
LVEF decreased. For these two relationships figure 5.10 shows: 
¢ That when the viral load and LVEF increased (total of 15 
cases), the highest percentages of cases were on any 
combination of ART (46.67%). The second highest point was 
for those cases that were on no ART (33.33%). Those cases 
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that were at first on no ART, but started with ART before the 
next visit, amounted to 20%. There were no cases (0%) in 
which the patients were at first on ART, but stopped the 
treatment before the next visit. 
¢ That when the viral load and LVEF decreased (total of 20 
cases), the highest point occurred in those cases that were on 
ART during both visits (55%). The second highest point 
occurred in those cases that went onto ART before the second 
follow-up (30%). Only 15% were on no ART. There were no 
(0%) cases in which the patients were first on ART and then 
stopped taking it before the next visit. 
There were three different relationships between the viral load and the 
LVEF where one of the variables stayed constant. First, the viral load 
stayed constant and the LVEF increased, secondly the viral load stayed 
constant and the LVEF decreased, and thirdly the viral load increased 
and the LVEF stayed constant. For these three relationships figure 5.10 
shows that: 
¢ When the viral load stayed constant and the LVEF increased (total 
number of cases = 17), the viral load of 14 cases stayed constant 
below 400 RNA copies/ml, and the viral load of three cases stayed 
constant above 750 000 RNA copies/ml. The highest percentage 
of cases were on any combination of ART during both follow-up 
visits (76.47%). In all of these 76.47% of cases, the viral load 
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stayed constant below 400 RNA copies/ml. The second highest 
point occurred in those cases that were on no ART (17.65%). In 
all of these 17.65% of cases, the viral load stayed constant above 
750 000 RNA copies/ml. 5.88% of cases went from no ART onto 
ART before the next follow-up. The viral load of these percentage 
of cases stayed constant above 750 000 RNA copies/mi. Out of 
these findings one could say that the highest point was when the 
the viral load stayed constant below 400 RNA copies/ml, while the 
LVEF increased, and they were on ART from one visit to another. 
This shows a very positive influence of the ART on the viral load, 
because the goal is to keep the viral load below 400 RNA 
copies/ml for as long as possible. 
¢ When the viral load stayed constant and the LVEF decreased (total 
number of cases = 13). Out of these thirteen cases, the viral load 
of three cases stayed constant above 750 000 RNA copies/ml and 
the viral load of ten cases stayed constant below 400 RNA 
copies/ml. The highest percentage of cases were on any 
combination of ART from one follow-L!P to the next (84.61%). 
From this 84.61% of cases the viral load of 76.92% cases was 
below 400 RNA copies/ml, and the viral load of 7.69% cases was 
above 750 000 RNA copies/ml. The second highest percentages of 
cases were on no ART (15.38%). All of the viral loads of these 
15.38% cases were above 750 000 RNA copies/ml. There were no 
(0%) cases that went onto ART (that was at first on no ART and 
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then went onto ART before the next visit), or that were on ART 
and then stopped the treatment before the next visit 
~ When the viral load increased and the LVEF stayed constant (total 
number of cases = 2). This was an indeterminate relationship, 
because there was no definite relationship between these two 
cases and the LVEF did not stay constant at the same value in the 
two cases. Both of these cases were on ART from one visit to 
another. Therefore the very high percentage of 100%. 
In summarizing all the findings from figure 5.10, one can see that 
when the viral load stayed constant below 400 RNA copies/ml, all 
cases were on any combination of ART, or went onto ART (at the first 
visit the patient was on no ART, but went onto ART before the next 
visit). In the cases in which the viral load stayed constant above 750 
000 RNA copies/ml, none of the cases were on ART (no ART). This 
shows a very positive influence of ART on the viral load, since the 
goal is to get the viral load below 400 RNA copies/ml and keep it 
there for as long as possible. In all the cases in which the viral load 
decreased, the highest and second highest percentage of cases were 
all either on ART on both visits, or they went onto ART (at first they 
were on no ART, but went onto ART before the next visit). This also 
showed a positive influence of ART on the viral load. One should then 
expect that when the patients were on no ART, the viral load would 
have increased or stayed constant above 750 000 RNA copies/ml. 
There were two exceptions to this positive influence of ART on the 
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viral load. This was seen in the cases in which the viral load 
increased: the viral load increased, although the highest percentage 
of cases were on ART and the second highest percentage of cases 
were on no ART. One would have expected that the highest 
percentage of cases would not be ART. A possible explanation might 
be that the large number of patients that were on ART might have 
developed viral resistance, and therefore the viral load increased, 
even though the patients were on ART. Regarding the second highest 
point, the patients were on no ART, and their viral load increased. 
When the LVEF increased, decreased, or stayed constant, there were 
no direct influences of the ART on the LVEF. Figure 5.3 shows there is 
an indirect proportional relationship between the viral load and the 
LVEF. From figure 5.3 and figure 5.10 one could say that if the ART 
had a positive effect on the viral load (Le. viral load decreased) then 
there is a large possibility that the viral load reduction would cause 
the LVEF to increase. Thus the ART had an influence on the viral load 
and the viral load had an influence on the LVEF. ART therefore has an 
indirect positive effect on the LVEF. These ,findings correlate with the 
findings of Barbaro (1998b). He found that the incidence of dilated 
cardiomyopathy was influenced more by the extent of 
immunodeficiency than by the type of antiretroviral therapy (Barbaro, 
1998b). 
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In summarizing the findings from figure 5.11, one can see that at the 
highest points of cases that were on any combination of ART, the 
viral loads either decreased or stayed constant. In the relationships 
where the viral load stayed constant, the highest number of cases 
were on ART from one follow-up to another. In all of these cases, the 
viral load stayed constant below 400 RNA copies/ml, which is the goal 
viral load. In those cases that went onto ART (at first they were on no 
ART, but started ART before the next visit) the highest points also 
occurred when the viral load decreased. From this, one could say that 
the ART had a positive effect on the viral load. When the cases were 
on no ART, the highest point occurred when the viral load decreased 
and the LVEF increased. The reason for this is not clear. It might be 
due to life changes, etc., but this cannot be confirmed. If one looks at 
the second highest points of the cases that were on no ART, the viral 
, 
load did increase. The one case in which the patient was first taking 
ART, but discontinued the treatment, the viral load increased. 
On the other hand, there was no direct influence of the ART on the 
LVEF. One could only say, as was seen in figure 5.3, that the viral 
load and the LVEF had an indirect proportional relationship to each 
other in most cases and that the ART had a positive effect on the 
viral load in most cases. Therefore, if the ART improved the viral load 
(Le. viral load decreases), then one would expect to see that the 
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LVEF would increase. Thus the ART did have a positive influence on 
the viral load and, via the viral load, a positive influence on the LVEF. 
Barbaro (1998b) found that among patients who received zidovudine 
(from the NRTI group), the incidence of cardiomyopathy was greater 
in those with a CD4 cell count of less than 300 cell/ml, but this same 
study also mentioned that the difference observed in the incidence of 
dilated cardiomyopathy among the risk groups was influenced more 
by the extent of immunodeficiency than by the type of ART. Upshultz 
(1998) also indicated that zidovudine (from the NRTI group) neither 
worsened nor ameliorated progressive cardiac changes in HIV 
infected patients. Millei et al. (1998) mentioned that myocardial 
dysfunction may also result indirectly via drugs such as zidovudine. 
Figure 5.12 shows that a greater percentage of cases with a below 
normal LVEF (:552%) were on no ART, compared with those who 
were on ART. The percentage of cases in both groups (those who 
were on ART and those who were on no A,RT) increased as the CD4 
cell count increased up to the cut-off point of :5350 cells/ml, and then 
steeply decreased when the CD4 cell count reached the >350 cells/ml 
cut-off point (see figure 5.13). It was also shown that the only cut-off 
point that had any statistical importance (according to the 95% 
Wilson confidence interval of the difference) was the cut-off point of 
250 cells/ml. Even though the clinical importance of this confidence 
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interval [0.60% ; 33.80%] is doubtful, it should still be considered 
since the upper limit of the 95% confidence interval is high. 
Figure 5.14 shows that a higher percentage of cases with below 
normal LVEF were on ART in comparison with those with below 
normal LVEF that were on no ART up to the cut-off point of 100 000 
RNA copies/ml. When the viral load was > 100 000 RNA copies/ml, 
there was a sudden decrease in the percentage of cases with a below 
normal LVEF who were on ART, to a point that was below those cases 
who were on no ART. There was also a steady increase in the 
percentage of cases with a below normal L VEF who were on no ART, 
after the cut-off point of 100 000 RNA copies/ml. There is no 
outstanding reason why this occurred, and further research of this 
specific aspect needs to be done. Of the 79 cases that had a below 
normal LVEF and a viral load to compare, 59.5% were on no ART, 
and 40.5% used any combination of ART. 
Figure 5.6 up to figure 5.14 agree with the. findings of Pugliese et at. 
(2000). Pugliese et at. (2000) said that HAART (highly active 
antiretroviral therapy) does dramatically decrease the incidence of 
cardiac involvement in patients with HIV infection as opposed to 
patients only treated with one NRTI. The data obtained from this 
research study highlighted the fact that the ART did not have a direct 
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positive effect on the LVEF, but only indirectly via its positive effect 
on the CD4 cell count and the viral load. 
Clinical evidence of cardiac disease is usually overshadowed by 
manifestations in other organs, primarily the brain and lungs. As a 
consequence, the number of patients with AIDS, who have cardiac 
involvement at autopsy greatly exceeds the number with significant 
cardiac disease during life. Cardiac abnormalities are found at autopsy 
in two-thirds of patients with AIDS (Millei et al., 1998). The heart is 
often the unrecognized target of AIDS associated lesions even in the 
initial phase of the AIDS outbreak (1981 - 1989) (Millei et al., 1998). 
Although cardiac disease can occur at any stage of HIV infection, 
cardiac morbidity and mortality are more common in advanced stages 
(Millei et aI., 1998). The number of cardiomyopathies found at 
autopsies were more than those found during life. The most common 
reason for this finding is that the medical field is still very unaware of 
the fact that cardiac dysfunction occurrs in HIV/AIDS patients 
(Murphy et al., 1998). The researcher agrees with Tavazzi (2002) 
who said that echocardiography is by far the best diagnostic 
investigation also in asymptomatic patients. 
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6.1. Limiting Factors 
The main limiting factors that occurred during the study were: 
~ Patients that passed away before follow-up procedures 
were done. 
~ Patients that did not attend their follow-up 
appointments, or subsequently went to other physicians 
for follow-up visits. 
~ The high cost of doing a viral load study precluded some 
patients from having this done either at the time of 
diagnosis or during the 3 to 6 monthly follow-up visits. 
~ Some patients were admitted directly to hospital, where 
they usually received the blood tests, but the researcher 
was often unaware that they had been admitted and, as 
a result, did not do the LVEF study. 
~ The specific time period that the patients were on a 
specific regimen of ART was not always known. This was 
due to a few reasons: 
• The fact that the patients did not always attend 
their follow-up appointments as scheduled. 
• Some patients stopped their ART due to side 
effects, financial implications and other personal 
reasons at any time between the follow-up visits, 
and usually for an unknown period. 
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• Patients changed from one physician to another. 
• Some patients shared their monthly ART with 
their spouse, friends or partners. In these cases 
the physician could never be sure about the 
dosage and the time intervals at which the patient 
took the ART. 
• Some patients became mentally confused and 
were not able to take the ART as prescribed. Their 
caretakers did not always know how the ART 
should be given. 
• Some patients were not willing to be honest with 
the physician about the way he/she was taking 
the ART, if they were taking it at all. 
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6.2. Unanswered Questions that Arose 
<:> Why was the number of cases that were on no ART with 
viral load ~100 000 RNA copies/ml and with below normal 
LVEF (~52%) greater than the number of cases that were 
on ART (see figure 5.14)? 
<:> Why was the percentage of cases with below normal LVEF 
(~52%) less at the CD4 cell count cut-off point of 50 
cells/ml than at the CD4 cell count cut-off point of 100 
cells/ml (see figure 5.4)? 
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6.3. Shortcomings of this Research Project and 
Recommendations for Possible Future Research 
The study was possibly biased because a certain portion of the 
population was undoubtedly excluded from the study. This includes 
patients who do not have a medical aid or the financial capacity to 
consult a phYSician in private practice. 
Recommendations for future research will be: 
~ To extend a similar research project to include patients who 
consult public health facilities, thus excluding possible bias 
owing to financial implications. 
~ To compile a similar research project over a longer period 
of time. 
~ To compare the influence of other variables on the CD4 cell 
count, viral load and LVEF. Examples of such variables 
would be body mass index and other opportunistic 
infections. 
~ To compile a similar research project, with participants who 
are under the supervision of a research group. This can 
help to monitor the patients' daily ART intake. This will 
result in research in which the time periods for specific ART 
regimens are known. 
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~ To compile a research project to test the possibility of a 
cardiotoxic effect of certain ART. 
~ To evaluate the extent of increase or decrease of CD4 cell 
count, viral load and LVEF, when the patients were on ART 
or on no ART over a period of time. 
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Conclusion 
I 
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This research project showed that there is a direct proportional 
relationship , between the CD4 cell count and the LVEF. The 
antiretroviral therapy had a direct positive influence on the CD4 cell 
count. Since the ART increased the CD4 cell count and the CD4 cell 
count is directly proportional to the LVEF, then the ART will indirectly 
have a positive influence on the LVEF. 
The occurrence of the LVEF below normal occurred most frequently 
when the CD4 cell count was :5100 cells/ml. Of all the patients whose 
LVEF was below normal, most were on no antiretroviral therapy. 
The viral load was shown to have an indirect proportional relationship 
to the LVEF. Antiretroviral therapy had a positive effect on the viral 
load (except for those cases in which the patient developed resistance 
to the ART). Since the successful use of ART caused the viral load to 
decrease and the viral load and the LVEF are indirectly proportional to 
each other, one could say that the ART does not have a direct 
positive influence on the LVEF, but only via ,the viral load. 
The occurrence of the LVEF being below normal occurred most 
frequently when the viral load was ~100 000 RNA copies/ml. Of all 
the patients whose LVEF was below normal, most were on 
antiretroviral therapy, up to the viral load cut-off point of :5100 000 
RNA copies/ml. When the viral load exceeded the cut-off point of 100 
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000 RNA copies/ml, the patients who were on no ART with a LVEF 
below normal exceeded those who were on ART. 
To conclude, this study confirms the findings of several previous 
authors (Currie et aI., 1998; Schlant & Alexander, 1994; Lipshultz et 
aI., 1998; Barbaro 1998b; Hivdent, 1998; Millei et al., 1998; Murphy, 
1999; Rerkpattanapipat et aI., 2000; Pugliese et aI., 2000; ACierno, 
1989; Warkentin, 1998; Yunis et a/., 1998) in showing the prevalence 
of left ventricular dysfunction and dilated cardiomyopathy among 
patients with HIV infection and AIDS. The prevalence is higher in 
patients with advanced disease, the most significant cut-off points 
being a CD4 cell count at or below 100 cel/s/ml and a viral load above 
100000 RNA copies/ml. The study also showed the positive impact of 
ART on left ventricle function, where by reducing the viral burden and 
therefore allowing the CD4 cell count to rise, the left ventricle 
function improved. Most of the patients with impaired left ventricular 
function were asymptomatic. 
The physician treating patients with HIV infection should therefore 
have a high index of suspicion for cardiac dysfunction. Careful clinical 
examination is, as always, of utmost importance. Echocardiographic 
examination in patients with CD4 cell counts at or below 100 will 
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increase the diagnostic field and therefore ensure that patients get 
appropriate medication and treatment. 
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Appendix A: Results 
Table A.l: Percentage of cases with LVEF S 52% when the 
CD4 cell count was at certain cut-off pOints. 
Out of the population there were 114 cases of patients with CD4 cell 
counts and LVEF studies in which the LVEF study was below normal 
(~52%), and 337 cases of patients with CD4 cell counts and LVEF 
studies in which the LVEF study was within the normal range (>52% 
- 75%). This resulted in a total of 451 cases. 
The difference in the percentage was calculated via the difference 
between the percentage of cases with below normal LVEF in cases 
with a CD4 cell count less or equal to (~) the cut-off pOint, and a CD4 
cell count greater than the cut-off point. 
The cut-off points for the CD4 cell counts were SO, 100, 150, 200, 
250,300, 350, >350 cells/ml. The >350 cells/ml cut-off pOint (i.e. ° -
>350) included all the cases defined above. 
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Part 1: 
I LVEF 
~i; S52% >52% Total Total 114 337 451 
L VEF. Lett venlTide ejec/Jon ffactjon (normal value. >52% - 75%) 
Calculations: 
Q Percentage of cases with below normal LVEF (:552%) in all the 
above defined cases: 114.;- (114 + 337) x 100= 25.28%. 
Part 2-
-
I LVEF 
S52% >52% Total 
~I; S50 33 59 92 >50 81 278 359 
114 337 451 Total 
LVEF. Lett venlTide ejec/Jon fraction (normal value. >52% - 75%) 
Calculations: 
Q Percentage of cases with below normal LVEF (:552%) in cases 
with CD4 cell count :550 is: 33 .;- (33 + 59) x 100= 35.87%. 
Q Percentage of cases with below normal LVEF (:552%) in cases 
with CD4 cell count >50 is: 81 .;- (81 + 278) x 100= 22.56%. 
Q Difference: 13.3%. 
Q 95% Wilson confidence interval for the % difference: [3.2% ; 
22.6%] 
Part 3: 
I LVEF 
S52% >52% 
~il S100 57 86 >100 57 251 
114 337 Total 
LVEF. Lett venlTide ejection fraction (normal value. >52% - 75%) 
Total 
143 
308 
451 
CENTRAL UNIVERSITY OF 
TECHNOLOGY, FREE STATI 
SENTRALE UNIVERSITEIT 
VIR TEGNOlOOIE, VRYSTAAl 
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Calculations: 
¢ Percentage of cases with below normal LVEF (::552%) in cases 
with CD4 .cell count ::5100 is: 57 -7 (57 + 86) x 100= 39.86%. 
¢ Percentage of cases with below normal LVEF (::552%) in cases 
with CD4 cell count> 100 is: 57 -7 (57 + 251) x 100= 18.51%. 
¢ Difference: 21.4% 
¢ 95% Wilson confidence interval for the % difference: [12.4% ; 
30.4%] 
Part 4" 
" 
I LVEF 
S52% >52% Total 
!Ii S150 70 119 189 >150 44 218 262 
114 337 451 Total 
LVEF: Left ventride ejection n-actlOn (nannal value: >52% -75%) 
Calculations: 
¢ Percentage of cases with below normal LVEF (::552%) in cases 
with CD4 cell count ::5150 is: 70 -7 (70 + 119) x 100 = 37.04%. 
¢ Percentage of cases with below normal LVEF (::552%) in cases 
with CD4 cell count> 150 is: 44 -7 (44 + 218) xl00 = 16.79%. 
¢ Difference: 20.2% 
¢ 95% Wilson confidence interval for the % difference: [12.0% ; 
28.4%] 
Part 5: 
I LVEF 
S52% >520/0 Total 
~il S200 77 146 223 >200 37 191 228 QUG/
u U 
Total 114 337 451 
LVEF. Left ventride ejection fraction (normal value. >52% -75%) 
Calculations: 
¢ Percentage of cases with below normal LVEF (::552%) in cases 
with CD4 cell count ::5200 is: 77 -7 (77 + 146) x 100 = 34.53%. 
¢ Percentage of cases with below normal LVEF (::552%) in cases 
with CD4 cell count >200 is: 37 -7 (37 + 191) x 100 = 16.23%. 
¢ Difference: 18.3% 
¢ 95% Wilson confidence interval for the % difference: [10.3% ; 
26.0%] 
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Part 6: .
I LVEF 
:$52% >520/0 Total 
!i~ :$250 82 171 253 >250 32 166 198 
114 337 451 Total 
LVEF: Len ventrtde ejection n-actJon (normal value: >52% - 75%) 
Calculations: 
<=:> Percentage of cases with below normal LVEF ($52%) in cases 
with CD4 cell count $250 is: 82 -:- (82 + 171) = 32.41%. 
<=:> Percentage of cases with below normal LVEF ($52%) in cases 
with CD4 cell count >250 is: 32 -:- (32 + 166) = 16.16%. 
<=:> Difference: 16.2% 
<=:> 95% Wilson confidence interval for the % difference:[ 8.3% ; 
23.7%] 
Part 7: 
I LVEF 
:$52% >52% Total 
!il :$300 93 201 294 >300 21 136 157 
114 337 451 Total 
LVEF. Len ventrtde ejection fraction (normal value. >52% - 75%) 
Calculations: 
<=:> Percentage of cases with below normal LVEF ($52%) in cases 
with CD4 cell count $300 is: 93 -:- (93 + 201) = 31.63%. 
<=:> Percentage of cases with below normal LVEF ($52%) in cases 
with CD4 cell count >300 is: 21 -:- (21 + .136) = 13.38%. 
<=:> Difference: 18.35% 
<=:> 95% Wilson confidence interval for the % difference: [10.3% ; 
25.4%] 
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Part 8: .
I LVEF 
::5520/0 >52% Total 
!;i ::5350 96 231 327 >350 18 106 124 
Total 114 337 451 
LVEF: Lett ventride ejection fractTon (normal value: >52% -75%) 
Calculations: 
9 Percentage of cases with below normal LVEF (:552%) in cases 
with CD4 cell count :5350 is: 96 -;- (96 + 231) = 29.36%. 
9 Percentage of cases with below normal LVEF (:552%) in cases 
with CD4 cell count >350 is: 18 -;- (18 + 106) = 14.52%. 
9 Difference: 14.8%. 
9 95% Wilson confidence interval for the % difference: [6.2% ; 
22.1%]. 
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Table A.2: Percentage of cases with LVEF S 52% when the 
virall,oad was at certain cut-off points. 
Out of the population there were 79 cases of patients with viral load 
studies and LVEF studies in which the LVEF study was below normal 
(::;52%), and 286 cases of patients with viral load studies and LVEF 
studies in which the LVEF study was within the normal range (>52% 
- 75%). This resulted in a total of 365 cases. 
The difference in the percentage of cases was calculated as the 
difference between the percentage of cases with below normal LVEF 
in cases with viral load larger than the cut-off point and the viral load 
less or equal to (::;) the cut-off point. 
The ranges in which the viral load (PCR-method) can be measured, 
are between <400 RNA copies/ml (or in some cases <50 
RNA/copies/ml when the doctor requested the ultra HIV PCR viral 
load test) and > 750 000 RNA copies/ml. The cut-off pOints in this 
study were::; 1 000 (Le. ::; 103), 10 000 (Le.' 104), 100 000 (Le. 105) 
and 1 000 000 (Le. 106). Therefore the lowest value of viral load 
«400 RNA copies/ml or <50 RNA copies/ml in some cases) was 
included in the ::; 1 000 cut-off point, and the highest value of viral 
load (>750 000 RNA copies/ml) was included in the cut-off pOint of 
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< 1 000 000. The cut-off point of < 1 000 000 will therefore include all 
the above defined cases (Le. 0 - 1 000 000). 
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Part 1 
I LVEF I ~ :$52% >52% Total c E _ Zi-;;; ~~i Total 79 286 365 
Q LVEF. Left ventride ejection fracflon (normal value. >52% -75%) 
Calculations: 
¢ Prevalence of below normal LVEF (:552%) in cases with viral load 
:51 000000 is: 79 7 (79 + 286) x 100 = 21-64%_ 
Part 2' .
I LVEF 
~ < :$52% >52% Total ~~~ :$ 1000 15 62 77 ;; ~ .~ > 1000 64 224 288 
Total 79 286 365 
LVEF: Left ventride ejection frection (normal value: >52% - 75%) 
Calculations: 
¢ Percentage of cases with below normal LVEF (:552%) in cases 
with viral load :51 000 is: 157 (15 + 62) x 100 = 19_58%_ 
¢ Percentage of cases with below normal LVEF (:552%) in cases 
with viral load >1 000 is: 647 (64 + 224) x 100 = 22.22%. 
¢ Difference: 2.37% 
¢ 95% Wilson confidence interval for the % difference: [-8.4% ; 
11-7%] 
Part 3' .
I LVEF· i < :$52% >52% Total -~~ :$ 10000 19 110 129 QI 
> 10000 60 176 236 .. .~ 
:> u 
Total 79 286 365 
LVEF.· Left ventride ejection frection (normal value. >52% - 75%) 
Calculations: 
¢ Percentage of cases with below normal LVEF (:552%) in cases 
with viral load :510 000 is: 197 (19 + 110) x 100 = 14.73%. 
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¢ Percentage of cases with below normal LVEF (:552%) in cases 
with viral load >10000 is: 607 (60 + 176) x 100 = 25.42%. 
¢ Difference: 10.69% 
¢ 95% Wilson confidence interval for the % difference: [1.9% ; 
18.5%] 
Part 4: 
I 
:::52% >52% Total 
:::100000 27 172 199 
>100000 52 114 166 
Total 79 286 365 
LVEF. Len ventride ejection fraction (normal value. >52% -75%) 
Calculations: 
¢ Percentage of cases with below normal LVEF (:552%) in cases 
with viral load :5100000 is: 277 (27 + 172) x 100 = 13.57%. 
¢ Percentage of cases with below normal LVEF (:552%) in cases 
with viral load >100000 is: 527 (52 + 114) x 100 = 31.33%. 
¢ Difference: 17.76% 
¢ 95% Wilson confidence interval for the % difference: [9.2% ; 
26.2%]. 
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Table A.3: Percentage of cases that were on ART versus those 
on no ART at certain CD4 cell count cut-off points 
and with LVEF below normal (:$ 52%). 
Out of the population there were 114 cases of patients with CD4 cell 
counts and LVEF studies in which the LVEF study was below normal 
(:552). Out of these cases 67 cases were on no ART and 47 cases 
were on any combination of ART. 
The difference in the percentage was calculated as the difference 
between the percentage of cases with below normal LVEF in cases 
with a CD4 cell count less or equal to (:5) the cut-off pOint of those 
cases that were on no ART and those cases that were on any 
combination of ART. 
The cut-off points for the CD4 cell count were SO, 100, 150, 200, 250, 
300, 350, >350 cells/ml. The >350 cells/ml cut-off point (Le. 0 -
>350) included all the cases defined above. 
Part 1: 
CD4 cell count 
(celis/mil 
Total 
No ART 67 (58.8%) 
Any combination of ART 47 (41.2%) 
Tota/ 114 
© Central University of Technology, Free State
Influence of CD4, Viral load and ART on L VEF Steenkamp 149 
Part 2: 
CD4 cell count (cells/mll 
:$50 >50 Total 
No ART 20 47 67 
Any combination of ART 13 34 47 
Total 33 81 114 
Calculations: 
¢ Percentage of cases with CD4 cell count :550 cell/ml in cases that 
were on no ART is: 20 + (20 + 47) x 100 = 29.85% 
¢ Percentage of cases with CD4 cell count :550 cell/ml in cases that 
were on any combination of ART is: 13 + (13 + 34) x 100= 
27.66% 
¢ Difference: 2.2% 
¢ 95% Wilson confidence interval for the % difference: [-14.9% ; 
18.1%] 
Part 3: 
CD4 cell count (cellslml) 
:$100 >100 Total 
No ART 38 29 67 
Any combination of ART 19 28 47 
Total 57 57 114 
Calculations: 
¢ Percentage of cases with CD4 cell count :5100 cell/ml in cases that 
were on no ART is: 38 + (38 + 29) x 100 = 56.72% 
¢ Percentage of cases with CD4 cell count :5100 cell/ml in cases that 
were on any combination of ART is: 19 + (19 + 28) x 100 = 
40.43% 
¢ Difference: 16.3% 
¢ 95% Wilson confidence interval for the % difference: [-2.3% ; 
33.3%.] 
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Part 4' .
CD4 cell count(cells/ml) 
:S150 >150 Total 
No ART 44 23 67 
Any combination of ART 26 21 47 
Total 70 44 114 
Calculations: 
Q Percentage of cases with eD4 cell count ~150 cell/ml in cases that 
were on no ART is: 44 -;- (44 + 23) x 100 = 65.67% 
Q Percentage of cases with eD4 cell count ~ 150 cell/ml in cases that 
were on any combination of ART is: 26 + (26 + 21) x100 = 
55.32% 
Q Difference: 10.4% 
Q 95% Wilson confidence interval for the difference: [-7.5% ; 
27.8%] 
PartS: 
CD4 ~ell count {cellslml} 
:S200 >200 Total 
No ART 48 19 67 
Any combination of ART 29 18 47 
Total 77 37 114 
Calculations: 
Q Percentage of cases with eD4 cell count ~200 cell/ml in cases that 
were on no ART is: 48 -;- (48 + 19) x 100 = 71.64% 
Q Percentage of cases with eD4 cell count ~200 cell/ml in cases that 
were on any combination of ART is: 29 +(29 + 18) x 100 = 
61.7% 
Q Difference: 9.9% 
Q 95% Wilson confidence interval for the difference: [-7.2% ; 27%] 
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Part 6: 
CD4 cell count (cells/mll 
:5:250 >250 Total 
No ART 53 14 67 
Any combination of ART 29 18 47 
Total 82 32 114 
calculations: 
~ Percentage of cases with CD4 cell count :5250 cell/ml in cases that 
were on no ART is: 53 + (53 + 14) x 100 = 79.1% 
~ Percentage of cases with CD4 cell count :5250 cell/ml in cases that 
were on any combination of ART is: 29 + (29 + 18) x 100 = 
61.7% 
~ Difference: 17.4% 
~ 95% Wilson confidence interval for the % difference: [0.6% ; 
33.8%] 
Part 7: 
tD4 cell count (cellslml) 
:5:300 >300 Total 
No ART 58 9 67 
Any combination of ART 35 12 47 
Total 93 21 114 
Calculations: 
~ Percentage of cases with CD4 cell count :5300 cell/ml in cases that 
were on no ART is: 58 + (58 + 9) x 100 = 86.57% 
~ Percentage of cases with CD4 cell count :5300 cell/ml in cases that 
were on any combination of ART is: 35 +. (35 + 12) x 100 = 
74.47% 
~ Difference: 12.1% 
~ 95% Wilson confidence interval for the difference: [-2.4% ; 
27.4%] 
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PartS-
-
CD4 cell count (celis/mil 
:$350 >350 Tota/ 
No ART 60 7 67 
Any combination of ART 36 11 47 
Total 96 18 114 
Calculations: 
¢ Percentage of cases with CD4 cell count :5350 cell/ml in cases that 
were on no ART is: 60 -;- (60 + 7) x 100 = 89.55% 
¢ Percentage of cases with CD4 cell count :5350 cell/ml in cases that 
were on any combination of ART is: 36 -;- (36 + 11) x 100 = 
76.6% 
¢ Difference: 13.0% 
¢ 95% Wilson confidence interval for the % difference: [-0.8% ; 
27.8%] 
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Table A.4: Percentage of cases that were on ART versus those 
on no ART at certain viral load cut-off points and 
below normal LVEF (S52%). 
Out of the population there were 79 cases of patients with viral load 
studies and LVEF studies in which the LVEF study was below normal 
(~52%) . From the 79 cases, 47 cases were on no ART and 32 cases 
were on any combination of ART. 
The difference in the percentage was calculated as the difference 
between the percentage of cases with below normal LVEF in cases 
with viral load smaller or equal to the cut-off point for the cases that 
were on any combination of ART and for the cases that were on no 
ART. 
The ranges in which the viral load (PCR-method) can be measured, 
are <400 RNA copies/ml (in some cases <50 RNA copies/ml when the 
doctor requested the ultra HIV PCR viral load test) up to >750 000 
RNA copies/ml. The cut-off points in this study were ~1 000 (Le. 
~103), 10 000 (Le. 104), 100 000 (Le. 105) and 1 000 000 (Le. 106). 
Therefore the lowest value of viral load «400 RNA copies/ml) was 
included in the <1 000 cut-off point, and the highest value of viral 
load (>750 000 RNA copies/ml) was included in the cut-off pOint of 
<1 000000. The cut-off point of <1 000000 would therefore include 
all the above defined cases (Le. 0 - 1 000 000). 
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Part 1-
-
Viral LOild (RNA 
cQRieslml) 
Total 
No ART 47 
Any combination of ART 32 
Total 79 
Calculations: 
q Of the 79 cases with below normal LVEF, 47 (59.5%) used no ART 
and 32 (40.5%) used any combination of ART. 
Part 2-
-
Viral Load (RNA co ies/mn 
~1 000 >1000 Total 
No ART 1 46 47 
Any combination of ART 14 18 32 
Total 15 64 79 
Calculations: 
q Percentage of cases with viral load ::51 000 RNA copies/ml in cases 
that were on no ART is: 1 + (1 + 46) x 100 = 2.13% 
q Percentage of cases with viral load ::51000 RNA copies/ml in cases 
that were on any combination of ART is: 14 + (14 + 18) x 100 = 
43.75% 
q Difference: 41.6% 
q 95% Wilson confidence interval for the % difference: [23.6% ; 
58.6%] 
Part 3-
-
Viral Load (RNA co ies/mn 
~10000 >10000 Total 
No ART 3 44 47 
Any combination of ART 16 16 32 
Total 19 60 79 
Calculations: 
q Percentage of cases with viral load ::510000 RNA copies/ml in 
cases that were on no ART is: 3 + (3 + 44) x 100 = 6.38% 
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~ Percentage of cases with viral load ~ 10 000 RNA copies/ml in 
cases that were on any combination of ART is: 16 + (16 + 16) x 
100= 50% 
~ Difference: 43.62% 
~ 95% Wilson confidence interval for the % difference: [9.5% ; 
60.5%] 
Part 4: 
Viral Load (RNA cooies/mn 
:5:100000 >100000 Total 
No ART 10 37 47 
Any combination of ART 17 15 32 
Total 27 52 79 
Calculations: 
~ Percentage of cases with viral load ~100 000 RNA copies/ml in 
cases that were on no ART is: 10 + (10 + 37) x 100 = 21.28% 
~ Prevalence of viral load ~100 000 RNA copies/ml in cases that 
were on any combination of ART is: 17 + (17 + 15) x 100 = 
53.13%. 
~ Difference: 31.85%. 
~ 95% Wilson confidence interval for the % difference: [10.3% ; 
50.4%]. 
© Central University of Technology, Free State
Influence of eM, Vira/Ioad and ART on L VEF 5teenkamp 156 
AppendixB: Consent Forms and Practice Registration 
Form. 
B.l. Subject Information Sheets and Statements of Informed 
Consent. 
B.l.l. Informed Consent 
I, ---;;=-:-:=c:=~===---', date of birth, _______ _ 
Patient's name in block letters 
hereby consent to participate in the research trial: 
The influences of CD4 count, Viral Load and Antiretroviral Treatment 
on the Lett Ventricle Ejection Fraction of adult HIV/AIDS patients. 
Dr. M Makotoko has informed me in detail and in a comprehensible 
manner about the nature, importance and scope of the trial. I have 
read and understood the text of the patient information and this 
declaration of consent. My questions were answered by dr. M. 
Makotoko in sufficient detail. I understand that I reserve the right to 
withdraw my consent at any time without suffering any disadvantages 
and without my decision influencing my doctor-patient relationship. 
With my signature I also consent that mrs 5 Steenkamp may inspect 
my medical records for the purpose of the trial. 
My identity will be treated with absolute confidentiality and will not be 
imparted to third parties. 
Place 
Date Patient's signature 
Place 
Date Doctor's signature 
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B.1.2. Patient Information 
Thank you for agreeing to take part in this trial. 
I should like to point out that your participation is voluntary. You 
have the right to withdraw your consent to participate at any time 
without giving reasons and without any disadvantages arising in 
terms of further medical care. 
Your data will be passed on for scientific evaluation, but this will be 
entirely anonymous. 
For this trial to take place, we will need you to consent to the 
following: 
1. That your blood results and disease are made known to 
mrs 5 Steenkamp (clinical technologist) for the sole 
purpose of the trial. 
2. That your treatment plan is made known to mrs 5 
Steenkamp (clinical technologist) for the sole purpose of 
her research project. 
3. That mrs 5 Steenkamp may perform an echocardiogram on 
you to evaluate your heart status. This will be done free of 
charge if the echocardiogram is for the sole purpose of the 
resea rch project. 
4. That the above-mentioned data will be used for the 
research project. 
Your medical records will be treated with absolute confidentiality. 
Your name will not be made public. The data will be linked to a 
number and NOT to your personal detail. Thus nobody will know to 
whom the data belongs. 
We thank you very much for your co-operation. I will be glad to 
answer any other questions you might have. 
Dr. M. Makotoko 
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B.l.3. Tsebiso ya tumellano 
Nna __________________ , letsatsi la 
tswalo Ke fana ka tumello vaka ho nka karolo 
dipatlisisong tsena: 
Dr. M. Makotoko 0 ile a ntlhalosetsa ka botlalo bohlokwa Ie tsela eo 
dipatlisiso di tlilo etswang ka vona. Ke utluisisa hore patlisiso e na e 
batla eng, Ie hore tumello va ka va ho nka karolo e bolelang. Dipotso 
tsaka di ile tsa arajwa ka botlalo ke Dr. Makotoko. Ke utluisisa hore ke 
na Ie tokelo va ho tlohela hare ho sebaka ka ntle Ie ho fana ka 
tlhaloso, mme ho tlohela haka ho ke ke ha etsa hore tshebeletso vaka 
e be tsuong. 
Ho saena haka ho fana ka tumello va hore Mme S. Steenkamp aka 
bala mangolo aka a ngaka se bakeng sa dipatlisiso. Mabitso Ie 
manvolo aka a tla sebeletswa ka sephiri a sa fuwe batho babang. 
Tulo 
Letsatsi 
Tshaene ya monka karolo 
Tulo 
Letsatsi 
Tshaeno ya Ngaka 
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8.1.4. Tlhalosetso ho Mokudi 
Ke leboha ha 0 dumetse ho nka karolo patlisisong ena. 
Ke lakatsa hi) supa hore ho nka karolo ha hao ke boithaopi. 0 na Ie 
tokelo ya ho fetola maikutlo ho nkeng karolo nako Ie nako, kantle Ie 
ho fana ka mabaka. Tshebeletso yeo re 0 fang yona e ke ke ya angoa 
ke ho tlohela ha hao. 
Lipalo-palo tsa hao di tla fetisetswa ditekong tsa tlhaho (Scientific) 
empa sena setla etswa ho sa sebediswe mabitso a hao. 
Sebakeng sa patlisiso ena ho nka sebaka, retia lakatsa hore 0 
tsepamise maikutlo a hao ntlheng tsena: 
1 Sephetho sa madi a hao Ie lefu la hao ditla tsejwa ke 
mofumahadi S Steenkamp setsebi sa botegonologi bakeng 
sa patlisiso ena. 
2 Boemo ba bokudi ba hao bo tla tsejwa ke mofumahadi S. 
Steenkamp, setsibi sa botegonologi sebakeng sa ho 
ntshetsa pele dipathisiso tsena. 
3 Mofumahadi S. Steenkamp 0 tla etsa tlhathlobo ea pelo ea 
hao ea echocardiogram ntle Ie tefel/o. 
4 Dintlha tse ka hodimo ditla sebediswa bakeng sa diteko tsa 
porojeke. 
Ngodiso ya phodiso etla etswa ka lekunutu. Lebitso la hao Ie 
dintlha tsa hao ditla bapiswa Ie nomoro ya hao empa ese ya 
mosebetsi. Ha ho mang kapa mang yatla tseba hore dipalo-palo 
tseo ketsa mango 
Re leboha haholo bakeng la tshebedisano-mmoho ya hao Ie rona. 
Ke tla thabela ho araba potso efe kappa efe e tswang ho wena. 
Dr M MAKOTOKO 
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B.l.S. ToestemmingsYorm 
Ek, , geboortedatum gee 
hiermee my toestemming om deel te neem aan die navorsingsprojek: 
"The influence of CD4 cell count, Viral load and Antiretroviral Therapy 
on the Left Ventricle Ejection Fraction of Adult HIV/AIDS patients." 
Dr Makotoko het my volledig ingelig en in verstaanbare terme die 
wyse, die belangrikheid en die omvang van die studie verduidelik. Ek 
het die inligtingstuk gelees en dit verstaan en ook die verklaring van 
toestemming. My vrae sal so deeglik as moontlik beantwoord word 
deur Dr Makotoko. Ek verstaan dat ek ter eniger tyd kan onttrek van 
die studie sonder enige benadeling van my dokter-pasient 
verhouding. 
Met my handtekening gee ek ook toestemming dat Mev 5 Steenkamp 
my mediese rekords mag sien en gebruik vir die studie. My identiteit 
en pasientinligting sal konfidensieel hanteer word en nie aan 'n derde 
party deurgegee word nie. 
Plek 
Datum 
Pasient se handtekening 
Plek 
Datum 
Dokter se handtekening 
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8.1.6. Pasient Inligtingstuk 
Oankie dat u bereid is om deel van die projek te wees. 
Ek wys aan u uit dat u deelname vrywillig is. U het die reg om enige 
tyd van die projek te onttrek sonder om 'n rede te verskaf. U sal ook 
nie benadeel word in enige verdere behandeling nie. 
U data en inligting sal gebruik word vir wetenskaplike evaluering, 
waar die inligting anoniem hanteer word. 
Om die studie moontlik te maak het ons u toestemming nodig vir die 
volgende: 
1 Oat u bloeduitslae en siektetoestand bekend gemaak mag 
word aan Mev S Steenkamp (Kliniese Tegnoloog) vir die 
duur van die studie. 
2 Oat u behandeling bekend gemaak mag word aan Mev S 
Steenkamp (Kliniese Tegnoloog) vir die duur van die studie. 
3 Oat Mev S Steenkamp 'n eggokardiogram mag doen om u 
hartstatus te bepaal. Oaar is geen koste aan die toets 
verbonde nie en dit word uitsluitlik vir die studie gebruik. 
4 Oat al die bogenoemde inligting gebruik mag word vir die 
navorsingsprojek. 
U mediese rekords sal konfidensieel hanteer word. U naam sal nie 
bekend gemaak word nie. Die data sal verbind word met 'n 
nommer en nie met 'n persoon nie. 
Baie dankie vir u samewerking. Ek sal graag enige verdere vrae 
beantwoord wat u mag he oor die studie. 
Dr. M. Makotoko 
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B.2. Practice Registration Form 
PATIENT DATA 
Steenkamp 162 
Surname: (Mr/Mrs/Miss), ________________ _ 
Full name: 
ID Nr.: 
REFERRED BY: 
PERSON RESPONSIBLE FOR ACCOUNT 
Surname (Mr/Mrs/Miss): 
Full name: ____________________ _ 
Postal address: 
__ ~~---------------Code---­
Home address: 
--,---,-...,..--________________ Code: ___ _ 
Tel: (H) ________ (W) _______ _ 
Cell Phone: 
Employer: 
Medical aid name: _________ Nr. 
Date: _________ ,Signature _______ _ 
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Append;xC: Example of the Raw Data 
~ 
11 
E 
::J 
'" 0:: 3 ~ t. 5 0:: ~ " III B f g ... 5 " 
'" 
.. w 5 :. 8 
'" 
S ~ z ~ > 
'"' 
z z ... 
1 590828 F 2001/03/15 607521 91 NO ART 
590828 F 2001/09/17 57 Didanosine, Efavirenz 
Stavudine 
590828 F 2001/09/18 593824 55 Didanosine, Efavirenz 
Stavudine 
590828 F 2002/05/02 1410 164 71 Didanosine, Efavtrenz 
Stavudine 
590828 F 2002/05/03 119 Didanosine, Efavirenz 
Stavudine 
590828 F 2002/07/09 60 No ART 
590828 F 2002/09/28 26 Efavirenz Ritonavir, Indinavir 
590828 F 2002/10/01 30 Didanosine, Efavirenz 
Stavudine 
590828 F 2002/10/14 47 Didanosine, Efavirenz 
Stavudine 
590828 F 2002/10/23 Oidanosine, Efavirenz 
Stavudine 
2670730 M 1999/04/10 346 NO ART 
670730 M 1999/04/13 2580 No ART 
670730 M 1999/08/20 2% Didanosine, Hydroxyurea 
Stavudine 
670730 M 1999/08/28 627 Didanosine, Hydroxyurea 
Stavudine 
670730 M 1999/12/09 101 000 250 65 Didanasine, Hydroxyurea 
Stavudine 
670730 M 2001/12/21 68 588 202 Efavirenz Ritonavir, Indinavir 
670730 M 2002/02/04 58 Efavirenz Ritonavir, Indinavir 
670730 M 2002/03/11 50500462 Efavirenz Ritonavir, Indinavir 
670730 M 2002/05/24 526 Efavirenz Ritonavir, Indinavir 
670730 M 2002/07/29 123000 Efavirenz Ritonavir, Indinavir 
670730 M 2002/08/07 < 400 Efavirenz Ritonavir, Indinavir 
670730 M 2002/10/05 26100 168 lamivudine, Efavirenz 
Zidovudine 
670730 M 2003/01/05 203000 149 lamivudine, Efavirenz 
Zidovudine 
670730 M 2003/01/06 58 lamivudine, Efavirenz 
Zidovudine 
670730 M 2003/01/23 79 Efavirenl Ritonavir, Indinavir 
670730 M 2003/02/13 399 000123 Efavirenz Ritonavir, Indinavir 
670730 M 2003/02/16 Efavirenz Ritonavir Indinavir 
3 740516 F 2001/05/28 44 NO ART 
740516 F 2001/05/29 57 No ART 
740516 F 2001l08j03 31 No ART 
4 571105 F 2003/04/14 17100 314 58 No ART 
5720203 M 2003/01/24 386000 177 No ART 
720203 M 2003/01/27 214 No ART 
720203 M 2003/03/03 65 Didanosine, Efavirenz 
Stavudine 
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-
.! 
E 
::J ... c: ! ~ 1- 5 c: -.. .. B i! ! II. 5 .. :c .. '" 5 :. 8 eX .. > ~ z ~ co ... z z ... 
6640406 M 2002/05/27 63 No ART 
640406 M 2002/07/02 > 750000 65 Didanosine, Efavirenz 
Stavudine 
640406 M 2002/08/15 60 Didanosine, Efavirenz 
Stavudine 
7 710502 F 2000/08/26 238 No ART 
710502 F 2000/09/13 601624 52 No ART 
710502 F 2000/09/15 43 Lamivudine, 
Zidovudine 
710502 F 2000/11/21 32 Lamivudine, 
Zidovudine 
710502 F 2000/12/07 148 000 Lamivudine, 
Zidovudine 
710502 F 2000/12/21 5578 124 Lamivudine, Nevirapine 
Zidovudine 
710502 F 2001/01/16 428000 70 Lamivudine, Nevirapine 
Zidovudine 
710502 F 2001/02/13 67 Lamivudine, Nevirapine 
lidovudine 
710502 F 2001/02/14 295000 6 Didanosine, 
Stavudine 
710502 F 2001/07/09 675000 119 Didanosine, 
Stavudine 
710502 F 2001/08/16 187 Oidanosine, 
Stavudine 
710502 F 2001/09/27 164 000 126 Lamivudine, 
Zidovudine 
710502 F 2002/01/21 30 Lamivudine, 
Zidovudine 
710502 F 2002/09/07 Lamivudine, 
Zidovudine 
8 731002 F 2002/08/28 183 67 No ART 
731002 F 20020903 26100 No ART 
9 790323 F 2001/08/17 364 887 15 No ART 
790323 F 2002/08/20 331 Didanosine, 
Stavudine 
790323 F 2002/12/06 8830 514 64 Didanosine, 
Stavudine 
10 671110 M 1999/11/29 312587 68 56 No ART 
671110 M 2000/08/03 81 Didanosine, Nevirapine 
Stavudine 
671110 M 2000/08/07 52 Didanosine, Nevirapine 
Stavudine 
11 531113 M 2002/03/25 267874 174 48 No ART 
531113 M 2002/04/17 No ART 
12 731105 F 2000/10/02 296990 1 62 NO ART 
731105 F 2001/08/13 NO ART 
,~, 
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